WO1998053812A1 - Inhibitors of naaladase enzyme activity - Google Patents
Inhibitors of naaladase enzyme activity Download PDFInfo
- Publication number
- WO1998053812A1 WO1998053812A1 PCT/US1997/014347 US9714347W WO9853812A1 WO 1998053812 A1 WO1998053812 A1 WO 1998053812A1 US 9714347 W US9714347 W US 9714347W WO 9853812 A1 WO9853812 A1 WO 9853812A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- benzylhydroxyphosphinyl
- pentanedioic
- hydroxyphosphinyl
- pentanedioic acid
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract description 38
- 102000004190 Enzymes Human genes 0.000 title abstract description 10
- 108090000790 Enzymes Proteins 0.000 title abstract description 10
- 239000003112 inhibitor Substances 0.000 title description 63
- 150000001875 compounds Chemical class 0.000 claims abstract description 110
- -1 hydroxyphosphinyl Chemical class 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 44
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 103
- 206010028980 Neoplasm Diseases 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 42
- 125000003342 alkenyl group Chemical group 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 19
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 10
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 7
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- BGFHFJAUZXWNSA-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl-hydroxyphosphoryl]hexyl]pentanedioic acid Chemical compound CCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)CC1=CC=CC=C1F BGFHFJAUZXWNSA-UHFFFAOYSA-N 0.000 claims description 4
- BGEHMAARUOAFAE-UHFFFAOYSA-N 2-[1-[hydroxy(methyl)phosphoryl]ethyl]pentanedioic acid Chemical compound CP(=O)(O)C(C)C(C(O)=O)CCC(O)=O BGEHMAARUOAFAE-UHFFFAOYSA-N 0.000 claims description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- AUASMYFDSORXAL-UHFFFAOYSA-N 2-[1-[hydroxy(phenyl)phosphoryl]heptyl]pentanedioic acid Chemical compound CCCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)C1=CC=CC=C1 AUASMYFDSORXAL-UHFFFAOYSA-N 0.000 claims description 3
- XJGGXAFLPLVIBA-UHFFFAOYSA-N 2-[1-[hydroxy-[(2,3,4,5,6-pentafluorophenyl)methyl]phosphoryl]heptyl]pentanedioic acid Chemical compound CCCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)CC1=C(F)C(F)=C(F)C(F)=C1F XJGGXAFLPLVIBA-UHFFFAOYSA-N 0.000 claims description 3
- ZESXUVOYSOPBPM-UHFFFAOYSA-N 2-[2-[benzyl(hydroxy)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(C)P(O)(=O)CC1=CC=CC=C1 ZESXUVOYSOPBPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims description 3
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 3
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 3
- IOYBOEIDZBUIIS-UHFFFAOYSA-N 2-(1-phosphonobut-2-enyl)pentanedioic acid Chemical compound CC=CC(P(O)(O)=O)C(C(O)=O)CCC(O)=O IOYBOEIDZBUIIS-UHFFFAOYSA-N 0.000 claims description 2
- XMUWSTAUNIOSEA-UHFFFAOYSA-N 2-[1-[(4-fluorophenyl)methyl-hydroxyphosphoryl]but-3-enyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC=C)P(O)(=O)CC1=CC=C(F)C=C1 XMUWSTAUNIOSEA-UHFFFAOYSA-N 0.000 claims description 2
- NRNNGLSVDWFILP-UHFFFAOYSA-N 2-[1-[benzyl(hydroxy)phosphoryl]butyl]decanedioic acid Chemical compound OC(=O)CCCCCCCC(C(O)=O)C(CCC)P(O)(=O)CC1=CC=CC=C1 NRNNGLSVDWFILP-UHFFFAOYSA-N 0.000 claims description 2
- SXRNCHJELFIWFJ-UHFFFAOYSA-N 2-[1-[benzyl(hydroxy)phosphoryl]butyl]hexanedioic acid Chemical compound OC(=O)CCCC(C(O)=O)C(CCC)P(O)(=O)CC1=CC=CC=C1 SXRNCHJELFIWFJ-UHFFFAOYSA-N 0.000 claims description 2
- XYRCTOBGZMZMGF-UHFFFAOYSA-N 2-[1-[benzyl(hydroxy)phosphoryl]ethyl]nonanedioic acid Chemical compound OC(=O)CCCCCCC(C(O)=O)C(C)P(O)(=O)CC1=CC=CC=C1 XYRCTOBGZMZMGF-UHFFFAOYSA-N 0.000 claims description 2
- XQVKLVSCMAGJGA-UHFFFAOYSA-N 2-[1-[benzyl(hydroxy)phosphoryl]heptyl]octanedioic acid Chemical compound OC(=O)CCCCCC(C(O)=O)C(CCCCCC)P(O)(=O)CC1=CC=CC=C1 XQVKLVSCMAGJGA-UHFFFAOYSA-N 0.000 claims description 2
- QHPFJSJCOMKLJK-UHFFFAOYSA-N 2-[1-[benzyl(hydroxy)phosphoryl]pentyl]heptanedioic acid Chemical compound OC(=O)CCCCC(C(O)=O)C(CCCC)P(O)(=O)CC1=CC=CC=C1 QHPFJSJCOMKLJK-UHFFFAOYSA-N 0.000 claims description 2
- SCBIMYKFHBPTHT-UHFFFAOYSA-N 2-[1-[benzyl(hydroxy)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)CC1=CC=CC=C1 SCBIMYKFHBPTHT-UHFFFAOYSA-N 0.000 claims description 2
- FTGRNHCVTAFBRD-UHFFFAOYSA-N 2-[1-[butyl(hydroxy)phosphoryl]but-2-enyl]pentanedioic acid Chemical compound CCCCP(O)(=O)C(C=CC)C(C(O)=O)CCC(O)=O FTGRNHCVTAFBRD-UHFFFAOYSA-N 0.000 claims description 2
- FMSCCFTZVITIKO-UHFFFAOYSA-N 2-[1-[butyl(hydroxy)phosphoryl]pentyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCCC)P(O)(=O)CCCC FMSCCFTZVITIKO-UHFFFAOYSA-N 0.000 claims description 2
- GBTBFOKKNMXSQC-UHFFFAOYSA-N 2-[1-[cyclohexylmethyl(hydroxy)phosphoryl]hexyl]pentanedioic acid Chemical compound CCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)CC1CCCCC1 GBTBFOKKNMXSQC-UHFFFAOYSA-N 0.000 claims description 2
- NGNKYOADFJJEBR-UHFFFAOYSA-N 2-[1-[hydroxy(1h-indol-2-yl)phosphoryl]pentyl]pentanedioic acid Chemical compound C1=CC=C2NC(P(O)(=O)C(C(CCC(O)=O)C(O)=O)CCCC)=CC2=C1 NGNKYOADFJJEBR-UHFFFAOYSA-N 0.000 claims description 2
- QBJSXFLRGWPVTB-UHFFFAOYSA-N 2-[1-[hydroxy(1h-indol-3-yl)phosphoryl]hexyl]pentanedioic acid Chemical compound C1=CC=C2C(P(O)(=O)C(C(CCC(O)=O)C(O)=O)CCCCC)=CNC2=C1 QBJSXFLRGWPVTB-UHFFFAOYSA-N 0.000 claims description 2
- SCSKHTDKPHKLKV-UHFFFAOYSA-N 2-[1-[hydroxy(1h-indol-3-ylmethyl)phosphoryl]but-3-enyl]pentanedioic acid Chemical compound C1=CC=C2C(CP(O)(=O)C(CC=C)C(CCC(=O)O)C(O)=O)=CNC2=C1 SCSKHTDKPHKLKV-UHFFFAOYSA-N 0.000 claims description 2
- QTNLSQKPGJQMLS-UHFFFAOYSA-N 2-[1-[hydroxy(1h-indol-4-yl)phosphoryl]heptyl]pentanedioic acid Chemical compound CCCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)C1=CC=CC2=C1C=CN2 QTNLSQKPGJQMLS-UHFFFAOYSA-N 0.000 claims description 2
- LSQDEBGAGNIOKR-UHFFFAOYSA-N 2-[1-[hydroxy(1h-indol-4-ylmethyl)phosphoryl]pentyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCCC)P(O)(=O)CC1=CC=CC2=C1C=CN2 LSQDEBGAGNIOKR-UHFFFAOYSA-N 0.000 claims description 2
- IQWHPIBHPWGICP-UHFFFAOYSA-N 2-[1-[hydroxy(2-phenylethyl)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)CCC1=CC=CC=C1 IQWHPIBHPWGICP-UHFFFAOYSA-N 0.000 claims description 2
- FAOFCTNWKLLANR-UHFFFAOYSA-N 2-[1-[hydroxy(3-naphthalen-1-ylpropyl)phosphoryl]pentyl]pentanedioic acid Chemical compound C1=CC=C2C(CCCP(O)(=O)C(C(CCC(O)=O)C(O)=O)CCCC)=CC=CC2=C1 FAOFCTNWKLLANR-UHFFFAOYSA-N 0.000 claims description 2
- CIQVHMVMQXCBOU-UHFFFAOYSA-N 2-[1-[hydroxy(3-phenylprop-2-enyl)phosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)CC=CC1=CC=CC=C1 CIQVHMVMQXCBOU-UHFFFAOYSA-N 0.000 claims description 2
- GSCUVCCAMUHQJP-UHFFFAOYSA-N 2-[1-[hydroxy(3-phenylpropyl)phosphoryl]heptyl]pentanedioic acid Chemical compound CCCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)CCCC1=CC=CC=C1 GSCUVCCAMUHQJP-UHFFFAOYSA-N 0.000 claims description 2
- FQMNPUNTNWYELW-UHFFFAOYSA-N 2-[1-[hydroxy(3-phenylpropyl)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)CCCC1=CC=CC=C1 FQMNPUNTNWYELW-UHFFFAOYSA-N 0.000 claims description 2
- WTJRENUCLPANER-UHFFFAOYSA-N 2-[1-[hydroxy(3-pyridin-3-ylpropyl)phosphoryl]heptyl]pentanedioic acid Chemical compound CCCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)CCCC1=CC=CN=C1 WTJRENUCLPANER-UHFFFAOYSA-N 0.000 claims description 2
- JBNGGKWBVOJKSF-UHFFFAOYSA-N 2-[1-[hydroxy(4-naphthalen-1-ylbutyl)phosphoryl]heptyl]pentanedioic acid Chemical compound C1=CC=C2C(CCCCP(O)(=O)C(C(CCC(O)=O)C(O)=O)CCCCCC)=CC=CC2=C1 JBNGGKWBVOJKSF-UHFFFAOYSA-N 0.000 claims description 2
- CNOCUTLOJBCHFQ-UHFFFAOYSA-N 2-[1-[hydroxy(methyl)phosphoryl]but-2-enyl]heptanedioic acid Chemical compound CC=CC(P(C)(O)=O)C(C(O)=O)CCCCC(O)=O CNOCUTLOJBCHFQ-UHFFFAOYSA-N 0.000 claims description 2
- PHGIEYWXFATORR-UHFFFAOYSA-N 2-[1-[hydroxy(methyl)phosphoryl]hexyl]octanedioic acid Chemical compound CCCCCC(P(C)(O)=O)C(C(O)=O)CCCCCC(O)=O PHGIEYWXFATORR-UHFFFAOYSA-N 0.000 claims description 2
- OWJRZHJPEINKLC-UHFFFAOYSA-N 2-[1-[hydroxy(methyl)phosphoryl]propyl]decanedioic acid Chemical compound CCC(P(C)(O)=O)C(C(O)=O)CCCCCCCC(O)=O OWJRZHJPEINKLC-UHFFFAOYSA-N 0.000 claims description 2
- ROPZRWJLJIKLIA-UHFFFAOYSA-N 2-[1-[hydroxy(methyl)phosphoryl]propyl]hexanedioic acid Chemical compound CCC(P(C)(O)=O)C(C(O)=O)CCCC(O)=O ROPZRWJLJIKLIA-UHFFFAOYSA-N 0.000 claims description 2
- SMHXHOTZBGZAFH-UHFFFAOYSA-N 2-[1-[hydroxy(naphthalen-1-ylmethyl)phosphoryl]ethyl]pentanedioic acid Chemical compound C1=CC=C2C(CP(O)(=O)C(C(CCC(O)=O)C(O)=O)C)=CC=CC2=C1 SMHXHOTZBGZAFH-UHFFFAOYSA-N 0.000 claims description 2
- RWAYIDWQPCISII-UHFFFAOYSA-N 2-[1-[hydroxy(oxolan-2-yl)phosphoryl]but-3-enyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC=C)P(O)(=O)C1CCCO1 RWAYIDWQPCISII-UHFFFAOYSA-N 0.000 claims description 2
- GCVWRLGICCBCDF-UHFFFAOYSA-N 2-[1-[hydroxy(propyl)phosphoryl]butyl]pentanedioic acid Chemical compound CCCP(O)(=O)C(CCC)C(CCC(O)=O)C(O)=O GCVWRLGICCBCDF-UHFFFAOYSA-N 0.000 claims description 2
- MEHWELMZYMWSFX-UHFFFAOYSA-N 2-[1-[hydroxy(pyridin-2-yl)phosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)C1=CC=CC=N1 MEHWELMZYMWSFX-UHFFFAOYSA-N 0.000 claims description 2
- NCMUDYBEHKZAFT-UHFFFAOYSA-N 2-[1-[hydroxy(pyridin-2-ylmethyl)phosphoryl]butyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCC)P(O)(=O)CC1=CC=CC=N1 NCMUDYBEHKZAFT-UHFFFAOYSA-N 0.000 claims description 2
- HJORJASCMBBEEA-UHFFFAOYSA-N 2-[1-[hydroxy(pyridin-3-yl)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)C1=CC=CN=C1 HJORJASCMBBEEA-UHFFFAOYSA-N 0.000 claims description 2
- IWCYKXNOUARVTM-UHFFFAOYSA-N 2-[1-[hydroxy(pyridin-3-ylmethyl)phosphoryl]but-2-enyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C=CC)P(O)(=O)CC1=CC=CN=C1 IWCYKXNOUARVTM-UHFFFAOYSA-N 0.000 claims description 2
- FHPIAQVEZBTMHN-UHFFFAOYSA-N 2-[1-[hydroxy(pyridin-4-yl)phosphoryl]butyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCC)P(O)(=O)C1=CC=NC=C1 FHPIAQVEZBTMHN-UHFFFAOYSA-N 0.000 claims description 2
- XUORNQOLKFEWSU-UHFFFAOYSA-N 2-[1-[hydroxy(pyridin-4-ylmethyl)phosphoryl]pentyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCCC)P(O)(=O)CC1=CC=NC=C1 XUORNQOLKFEWSU-UHFFFAOYSA-N 0.000 claims description 2
- IXFBBVFABJPSRW-UHFFFAOYSA-N 2-[1-[hydroxy(thiophen-3-yl)phosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)C=1C=CSC=1 IXFBBVFABJPSRW-UHFFFAOYSA-N 0.000 claims description 2
- FVSLCDSWCYWKRS-UHFFFAOYSA-N 2-[1-[hydroxy(thiophen-3-ylmethyl)phosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)CC=1C=CSC=1 FVSLCDSWCYWKRS-UHFFFAOYSA-N 0.000 claims description 2
- DVQBUVLBYAEOJO-UHFFFAOYSA-N 2-[1-[hydroxy(thiophen-3-ylmethyl)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)CC=1C=CSC=1 DVQBUVLBYAEOJO-UHFFFAOYSA-N 0.000 claims description 2
- BUBUQVYYWDVESJ-UHFFFAOYSA-N 2-[1-[hydroxy-[(3-methylphenyl)methyl]phosphoryl]butyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCC)P(O)(=O)CC1=CC=CC(C)=C1 BUBUQVYYWDVESJ-UHFFFAOYSA-N 0.000 claims description 2
- MFYZEGBSEMKDRW-UHFFFAOYSA-N 2-[1-[hydroxy-[(3-methylphenyl)methyl]phosphoryl]hexyl]pentanedioic acid Chemical compound CCCCCC(C(CCC(O)=O)C(O)=O)P(O)(=O)CC1=CC=CC(C)=C1 MFYZEGBSEMKDRW-UHFFFAOYSA-N 0.000 claims description 2
- PQWUQCCLXBUHOV-UHFFFAOYSA-N 2-[1-[hydroxy-[3-(oxolan-2-yl)propyl]phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)CCCC1CCCO1 PQWUQCCLXBUHOV-UHFFFAOYSA-N 0.000 claims description 2
- YMEMUUKZWAQHDE-UHFFFAOYSA-N 2-[1-[hydroxy-[[3-(trifluoromethyl)phenyl]methyl]phosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)CC1=CC=CC(C(F)(F)F)=C1 YMEMUUKZWAQHDE-UHFFFAOYSA-N 0.000 claims description 2
- UTAXKAHWANBGHG-UHFFFAOYSA-N 2-[1-[hydroxy-[hydroxy(phenyl)methyl]phosphoryl]but-2-enyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C=CC)P(O)(=O)C(O)C1=CC=CC=C1 UTAXKAHWANBGHG-UHFFFAOYSA-N 0.000 claims description 2
- RVRXQINONVXAPF-UHFFFAOYSA-N 2-[1-[hydroxy-[hydroxy(phenyl)methyl]phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)C(O)C1=CC=CC=C1 RVRXQINONVXAPF-UHFFFAOYSA-N 0.000 claims description 2
- FMMPHQYVTVBANK-UHFFFAOYSA-N 2-[2-[(4-fluorophenyl)-hydroxyphosphoryl]pent-3-enyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(C=CC)P(O)(=O)C1=CC=C(F)C=C1 FMMPHQYVTVBANK-UHFFFAOYSA-N 0.000 claims description 2
- KJEGRPRHSIKXOL-UHFFFAOYSA-N 2-[2-[hydroxy(4-naphthalen-2-ylbutyl)phosphoryl]pentyl]pentanedioic acid Chemical compound C1=CC=CC2=CC(CCCCP(O)(=O)C(CC(CCC(O)=O)C(O)=O)CCC)=CC=C21 KJEGRPRHSIKXOL-UHFFFAOYSA-N 0.000 claims description 2
- MNVMHWCGROANRL-UHFFFAOYSA-N 2-[2-[hydroxy(naphthalen-2-yl)phosphoryl]butyl]pentanedioic acid Chemical compound C1=CC=CC2=CC(P(O)(=O)C(CC(CCC(O)=O)C(O)=O)CC)=CC=C21 MNVMHWCGROANRL-UHFFFAOYSA-N 0.000 claims description 2
- IDZQNAVUYGNJAK-UHFFFAOYSA-N 2-[2-[hydroxy(thiophen-2-yl)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(C)P(O)(=O)C1=CC=CS1 IDZQNAVUYGNJAK-UHFFFAOYSA-N 0.000 claims description 2
- JZLCOYKAPWKPLW-UHFFFAOYSA-N 2-[2-[hydroxy-[methoxy(phenyl)methyl]phosphoryl]butyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(CC)P(O)(=O)C(OC)C1=CC=CC=C1 JZLCOYKAPWKPLW-UHFFFAOYSA-N 0.000 claims description 2
- GTYHBOYSDWRYBE-UHFFFAOYSA-N 2-[3-[hydroxy(methyl)phosphoryl]pentyl]nonanedioic acid Chemical compound CCC(P(C)(O)=O)CCC(C(O)=O)CCCCCCC(O)=O GTYHBOYSDWRYBE-UHFFFAOYSA-N 0.000 claims description 2
- GQQDNECNGSURAT-UHFFFAOYSA-N 2-[3-[hydroxy(oxolan-2-ylmethyl)phosphoryl]octyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCC(CCCCC)P(O)(=O)CC1CCCO1 GQQDNECNGSURAT-UHFFFAOYSA-N 0.000 claims description 2
- HVHYEPOSNTWHGZ-UHFFFAOYSA-N 2-[3-[hydroxy(thiophen-2-ylmethyl)phosphoryl]nonyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCC(CCCCCC)P(O)(=O)CC1=CC=CS1 HVHYEPOSNTWHGZ-UHFFFAOYSA-N 0.000 claims description 2
- JWKQDDRANAPMRZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-hydroxyphosphoryl]-phenylmethyl]pentanedioic acid Chemical compound C=1C=C(F)C=CC=1P(O)(=O)C(C(CCC(=O)O)C(O)=O)C1=CC=CC=C1 JWKQDDRANAPMRZ-UHFFFAOYSA-N 0.000 claims description 2
- LLMMUJYJHSXVDD-UHFFFAOYSA-N 2-[[benzyl(hydroxy)phosphoryl]-fluoromethyl]hexanoic acid Chemical compound CCCCC(C(O)=O)C(F)P(O)(=O)CC1=CC=CC=C1 LLMMUJYJHSXVDD-UHFFFAOYSA-N 0.000 claims description 2
- GKJKKZPZIFDWPB-UHFFFAOYSA-N 2-[[benzyl(hydroxy)phosphoryl]-fluoromethyl]octanedioic acid Chemical compound OC(=O)CCCCCC(C(O)=O)C(F)P(O)(=O)CC1=CC=CC=C1 GKJKKZPZIFDWPB-UHFFFAOYSA-N 0.000 claims description 2
- NAETYQNOQBGHGF-UHFFFAOYSA-N 2-[[hydroxy(methyl)phosphoryl]-phenylmethyl]nonanedioic acid Chemical compound OC(=O)CCCCCCC(C(O)=O)C(P(O)(=O)C)C1=CC=CC=C1 NAETYQNOQBGHGF-UHFFFAOYSA-N 0.000 claims description 2
- ZVKWQXZWYKVMGU-UHFFFAOYSA-N 2-[[hydroxy(oxolan-2-ylmethyl)phosphoryl]-phenylmethyl]pentanedioic acid Chemical compound C1CCOC1CP(O)(=O)C(C(CCC(=O)O)C(O)=O)C1=CC=CC=C1 ZVKWQXZWYKVMGU-UHFFFAOYSA-N 0.000 claims description 2
- ZOHUZULHQOYVHB-UHFFFAOYSA-N 2-[[hydroxy(thiophen-2-yl)phosphoryl]-phenylmethyl]pentanedioic acid Chemical compound C=1C=CSC=1P(O)(=O)C(C(CCC(=O)O)C(O)=O)C1=CC=CC=C1 ZOHUZULHQOYVHB-UHFFFAOYSA-N 0.000 claims description 2
- UYWMTHAYHWLBCT-UHFFFAOYSA-N 2-[fluoro-[hydroxy(1h-indol-4-yl)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(F)P(O)(=O)C1=CC=CC2=C1C=CN2 UYWMTHAYHWLBCT-UHFFFAOYSA-N 0.000 claims description 2
- KQYVEMWKLWFKJO-UHFFFAOYSA-N 2-[fluoro-[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(F)P(O)(=O)CCCC1=CC=CC=C1 KQYVEMWKLWFKJO-UHFFFAOYSA-N 0.000 claims description 2
- QTVFOVYPKBXEFJ-UHFFFAOYSA-N 2-[fluoro-[hydroxy(3-pyridin-3-ylpropyl)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(F)P(O)(=O)CCCC1=CC=CN=C1 QTVFOVYPKBXEFJ-UHFFFAOYSA-N 0.000 claims description 2
- AONMUDVDMNNSIK-UHFFFAOYSA-N 2-[fluoro-[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(F)P(O)(=O)C1=CC=CC=C1 AONMUDVDMNNSIK-UHFFFAOYSA-N 0.000 claims description 2
- FIXQDCFNDMNABV-UHFFFAOYSA-N 2-benzyl-3-[benzyl(hydroxy)phosphoryl]hexanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCC)C(C(O)=O)CC1=CC=CC=C1 FIXQDCFNDMNABV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- CFKPIGMLGNMRKQ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(1h-indol-2-yl)-2-methylnonanoic acid Chemical compound C=1C2=CC=CC=C2NC=1C(C)(C(O)=O)C(CCCCCC)P(O)(=O)CC1=CC=CC=C1 CFKPIGMLGNMRKQ-UHFFFAOYSA-N 0.000 claims description 2
- XWJWKGRZFZAQRJ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(1h-indol-2-yl)pentanoic acid Chemical compound C=1C2=CC=CC=C2NC=1C(C(O)=O)C(CC)P(O)(=O)CC1=CC=CC=C1 XWJWKGRZFZAQRJ-UHFFFAOYSA-N 0.000 claims description 2
- VXQNXNJOTLGRCN-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(1h-indol-3-yl)-2-methyl-3-propylnonanoic acid Chemical compound C=1NC2=CC=CC=C2C=1C(C)(C(O)=O)C(CCC)(CCCCCC)P(O)(=O)CC1=CC=CC=C1 VXQNXNJOTLGRCN-UHFFFAOYSA-N 0.000 claims description 2
- DRUABVFBUJXGBN-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(1h-indol-3-yl)hexanoic acid Chemical compound C=1NC2=CC=CC=C2C=1C(C(O)=O)C(CCC)P(O)(=O)CC1=CC=CC=C1 DRUABVFBUJXGBN-UHFFFAOYSA-N 0.000 claims description 2
- XTVPMGFHZGGOSA-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(1h-indol-4-yl)-2-methylbutanoic acid Chemical compound C=1C=CC=2NC=CC=2C=1C(C)(C(O)=O)C(C)P(O)(=O)CC1=CC=CC=C1 XTVPMGFHZGGOSA-UHFFFAOYSA-N 0.000 claims description 2
- ULVBEPJZPQZFEX-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(1h-indol-4-yl)hex-4-enoic acid Chemical compound C=1C=CC=2NC=CC=2C=1C(C(O)=O)C(C=CC)P(O)(=O)CC1=CC=CC=C1 ULVBEPJZPQZFEX-UHFFFAOYSA-N 0.000 claims description 2
- OFJATMQASSTFRI-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(2,3,4-trimethoxyphenyl)nonanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=C(OC)C(OC)=C1OC OFJATMQASSTFRI-UHFFFAOYSA-N 0.000 claims description 2
- RQARZNPFZGTQBR-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(2-naphthalen-1-ylethyl)hex-5-enoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1CCC(C(=O)O)C(CC=C)P(O)(=O)CC1=CC=CC=C1 RQARZNPFZGTQBR-UHFFFAOYSA-N 0.000 claims description 2
- MDDYOLBBAKMWBD-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(2-phenylethyl)hex-4-enoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C=CC)C(C(O)=O)CCC1=CC=CC=C1 MDDYOLBBAKMWBD-UHFFFAOYSA-N 0.000 claims description 2
- UXFRIBJXJAROTC-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(2-pyridin-3-ylethyl)pentanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CC)C(C(O)=O)CCC1=CC=CN=C1 UXFRIBJXJAROTC-UHFFFAOYSA-N 0.000 claims description 2
- NABYMBZOJLMPCD-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(oxolan-2-yl)butanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C)C(C(O)=O)C1CCCO1 NABYMBZOJLMPCD-UHFFFAOYSA-N 0.000 claims description 2
- LBHNKCFCSNIYNZ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-[2-(1h-indol-3-yl)ethyl]pentanoic acid Chemical compound C=1NC2=CC=CC=C2C=1CCC(C(O)=O)C(CC)P(O)(=O)CC1=CC=CC=C1 LBHNKCFCSNIYNZ-UHFFFAOYSA-N 0.000 claims description 2
- PAILCSCTLQYSIJ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-butylnonanoic acid Chemical compound CCCCCCC(C(CCCC)C(O)=O)P(O)(=O)CC1=CC=CC=C1 PAILCSCTLQYSIJ-UHFFFAOYSA-N 0.000 claims description 2
- BPEMISXVDAOJNN-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-cyclohexyl-2-methylbutanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C)C(C)(C(O)=O)C1CCCCC1 BPEMISXVDAOJNN-UHFFFAOYSA-N 0.000 claims description 2
- FSZRSVXSMZOFAW-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-cyclohexyl-3-ethylhexanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CC)(CCC)C(C(O)=O)C1CCCCC1 FSZRSVXSMZOFAW-UHFFFAOYSA-N 0.000 claims description 2
- OSCBFSNKNUJMKZ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-cyclohexyl-3-phenylpropanoic acid Chemical compound C1CCCCC1C(C(=O)O)C(P(O)(=O)CC=1C=CC=CC=1)C1=CC=CC=C1 OSCBFSNKNUJMKZ-UHFFFAOYSA-N 0.000 claims description 2
- FZSJGCBYJVOKAW-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-2-naphthalen-1-ylpentanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)(C(O)=O)C(CC)P(O)(=O)CC1=CC=CC=C1 FZSJGCBYJVOKAW-UHFFFAOYSA-N 0.000 claims description 2
- MZVGSRQWSKTWIJ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-2-naphthalen-2-ylhexanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(C)(C(O)=O)C(CCC)P(O)(=O)CC1=CC=CC=C1 MZVGSRQWSKTWIJ-UHFFFAOYSA-N 0.000 claims description 2
- TWUSLHVAVMZWIB-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-2-pyridin-2-ylnonanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCCC)C(C)(C(O)=O)C1=CC=CC=N1 TWUSLHVAVMZWIB-UHFFFAOYSA-N 0.000 claims description 2
- FGSSHUAVLGUSLW-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-2-pyridin-4-ylbutanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C)C(C)(C(O)=O)C1=CC=NC=C1 FGSSHUAVLGUSLW-UHFFFAOYSA-N 0.000 claims description 2
- BQKPEXCHNVUSLA-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-2-thiophen-2-ylhex-4-enoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C=CC)C(C)(C(O)=O)C1=CC=CS1 BQKPEXCHNVUSLA-UHFFFAOYSA-N 0.000 claims description 2
- YKGYXBAYPXFVCF-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-3-phenyl-2-pyridin-3-ylpropanoic acid Chemical compound C=1C=CN=CC=1C(C)(C(O)=O)C(P(O)(=O)CC=1C=CC=CC=1)C1=CC=CC=C1 YKGYXBAYPXFVCF-UHFFFAOYSA-N 0.000 claims description 2
- MXMZZIPMEAUNIQ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-3-propyl-2-pyridin-3-yloctanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCC)(CCCCC)C(C)(C(O)=O)C1=CC=CN=C1 MXMZZIPMEAUNIQ-UHFFFAOYSA-N 0.000 claims description 2
- GNKUTIXMWUSVNZ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methylhex-5-enoic acid Chemical compound OC(=O)C(C)C(CC=C)P(O)(=O)CC1=CC=CC=C1 GNKUTIXMWUSVNZ-UHFFFAOYSA-N 0.000 claims description 2
- OJJASUNREYKVJH-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-naphthalen-2-ylbutanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(C(O)=O)C(C)P(O)(=O)CC1=CC=CC=C1 OJJASUNREYKVJH-UHFFFAOYSA-N 0.000 claims description 2
- YYHODDBMQSKTJX-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-phenylbutanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C)C(C(O)=O)C1=CC=CC=C1 YYHODDBMQSKTJX-UHFFFAOYSA-N 0.000 claims description 2
- BAVIEKPAUKYMHR-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-phenylpentanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CC)C(C(O)=O)C1=CC=CC=C1 BAVIEKPAUKYMHR-UHFFFAOYSA-N 0.000 claims description 2
- JKUCHWFXHPAATP-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-propyloctanoic acid Chemical compound CCCCCC(C(CCC)C(O)=O)P(O)(=O)CC1=CC=CC=C1 JKUCHWFXHPAATP-UHFFFAOYSA-N 0.000 claims description 2
- ONPQUKVHMHGVJI-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-pyridin-2-yloctanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=N1 ONPQUKVHMHGVJI-UHFFFAOYSA-N 0.000 claims description 2
- GCKFMXPBRZXHBK-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-pyridin-3-ylnonanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=CN=C1 GCKFMXPBRZXHBK-UHFFFAOYSA-N 0.000 claims description 2
- MFADRBITJVKBKS-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-thiophen-3-ylnonanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCCC)C(C(O)=O)C=1C=CSC=1 MFADRBITJVKBKS-UHFFFAOYSA-N 0.000 claims description 2
- WIWPWSDEKFCCTN-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-thiophen-3-yloctanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCC)C(C(O)=O)C=1C=CSC=1 WIWPWSDEKFCCTN-UHFFFAOYSA-N 0.000 claims description 2
- OODNEBQCNHNOQE-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-3-ethyl-2-naphthalen-1-ylhex-4-enoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(O)=O)C(C=CC)(CC)P(O)(=O)CC1=CC=CC=C1 OODNEBQCNHNOQE-UHFFFAOYSA-N 0.000 claims description 2
- PVROPAZOPQOQDA-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-3-fluoro-2-methyl-2-pyridin-2-ylpropanoic acid Chemical compound C=1C=CC=NC=1C(C)(C(O)=O)C(F)P(O)(=O)CC1=CC=CC=C1 PVROPAZOPQOQDA-UHFFFAOYSA-N 0.000 claims description 2
- XYIXXEQKDUDAFD-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-3-fluoro-2-pyridin-3-ylpropanoic acid Chemical compound C=1C=CN=CC=1C(C(=O)O)C(F)P(O)(=O)CC1=CC=CC=C1 XYIXXEQKDUDAFD-UHFFFAOYSA-N 0.000 claims description 2
- MMROJCUMRUKPTA-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-3-pentyl-2-pyridin-4-ylnonanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCC)(CCCCCC)C(C(O)=O)C1=CC=NC=C1 MMROJCUMRUKPTA-UHFFFAOYSA-N 0.000 claims description 2
- UCXVOXMDALFTIS-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-4,4-dimethyl-2-(2-naphthalen-2-ylethyl)pentanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CCC(C(O)=O)C(C(C)(C)C)P(O)(=O)CC1=CC=CC=C1 UCXVOXMDALFTIS-UHFFFAOYSA-N 0.000 claims description 2
- NEDRKMCXQUEVSJ-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-4,4-dimethyl-2-[2-(oxolan-2-yl)ethyl]pentanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C(C)(C)C)C(C(O)=O)CCC1CCCO1 NEDRKMCXQUEVSJ-UHFFFAOYSA-N 0.000 claims description 2
- LFKJZRXXMYUHMT-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-4,4-dimethyl-2-thiophen-2-ylpentanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C(C)(C)C)C(C(O)=O)C1=CC=CS1 LFKJZRXXMYUHMT-UHFFFAOYSA-N 0.000 claims description 2
- WLGJBOQGAARASP-UHFFFAOYSA-N 3-[butyl(hydroxy)phosphoryl]-4,4-dimethyl-2-phenylpentanoic acid Chemical compound CCCCP(O)(=O)C(C(C)(C)C)C(C(O)=O)C1=CC=CC=C1 WLGJBOQGAARASP-UHFFFAOYSA-N 0.000 claims description 2
- JHBTZDXBDCVZOH-UHFFFAOYSA-N 3-[cyclohexyl(hydroxy)phosphoryl]-2-phenyloctanoic acid Chemical compound C1CCCCC1P(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=C1 JHBTZDXBDCVZOH-UHFFFAOYSA-N 0.000 claims description 2
- GSANHMROVLONBH-UHFFFAOYSA-N 3-[cyclohexylmethyl(hydroxy)phosphoryl]-2-phenylnonanoic acid Chemical compound C1CCCCC1CP(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=CC=C1 GSANHMROVLONBH-UHFFFAOYSA-N 0.000 claims description 2
- HZXDDPJYLSGDSG-UHFFFAOYSA-N 3-[cyclohexylmethyl(hydroxy)phosphoryl]-3-fluoro-2-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(F)P(O)(=O)CC1CCCCC1 HZXDDPJYLSGDSG-UHFFFAOYSA-N 0.000 claims description 2
- QTDFXVMPGPMNTK-UHFFFAOYSA-N 3-[hydroxy(1h-indol-2-yl)phosphoryl]-2,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(P(O)(=O)C=1NC2=CC=CC=C2C=1)C1=CC=CC=C1 QTDFXVMPGPMNTK-UHFFFAOYSA-N 0.000 claims description 2
- VQXLIGOXTLILRV-UHFFFAOYSA-N 3-[hydroxy(1h-indol-3-yl)phosphoryl]-2-phenylbutanoic acid Chemical compound C=1NC2=CC=CC=C2C=1P(O)(=O)C(C)C(C(O)=O)C1=CC=CC=C1 VQXLIGOXTLILRV-UHFFFAOYSA-N 0.000 claims description 2
- DFMCRTXAIZJXDI-UHFFFAOYSA-N 3-[hydroxy(1h-indol-4-yl)phosphoryl]-2-phenylpentanoic acid Chemical compound C=1C=CC=2NC=CC=2C=1P(O)(=O)C(CC)C(C(O)=O)C1=CC=CC=C1 DFMCRTXAIZJXDI-UHFFFAOYSA-N 0.000 claims description 2
- GBRXYBHQCDDAND-UHFFFAOYSA-N 3-[hydroxy(1h-indol-4-ylmethyl)phosphoryl]-2-phenylnonanoic acid Chemical compound C=1C=CC=2NC=CC=2C=1CP(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=CC=C1 GBRXYBHQCDDAND-UHFFFAOYSA-N 0.000 claims description 2
- IQCUXZXDANCQIN-UHFFFAOYSA-N 3-[hydroxy(3-naphthalen-1-ylpropyl)phosphoryl]-2-phenylhex-5-enoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1CCCP(O)(=O)C(CC=C)C(C(=O)O)C1=CC=CC=C1 IQCUXZXDANCQIN-UHFFFAOYSA-N 0.000 claims description 2
- NWYFUVJWEBIKKY-UHFFFAOYSA-N 3-[hydroxy(3-phenylprop-2-enyl)phosphoryl]-3-methyl-2-phenylnonanoic acid Chemical compound C=1C=CC=CC=1C=CCP(O)(=O)C(C)(CCCCCC)C(C(O)=O)C1=CC=CC=C1 NWYFUVJWEBIKKY-UHFFFAOYSA-N 0.000 claims description 2
- OEPHYJHFFXQELL-UHFFFAOYSA-N 3-[hydroxy(3-phenylpropyl)phosphoryl]-2-phenylhexanoic acid Chemical compound C=1C=CC=CC=1CCCP(O)(=O)C(CCC)C(C(O)=O)C1=CC=CC=C1 OEPHYJHFFXQELL-UHFFFAOYSA-N 0.000 claims description 2
- FNVILNFNVBPIEU-UHFFFAOYSA-N 3-[hydroxy(3-pyridin-3-ylpropyl)phosphoryl]-2-phenylbutanoic acid Chemical compound C=1C=CN=CC=1CCCP(O)(=O)C(C)C(C(O)=O)C1=CC=CC=C1 FNVILNFNVBPIEU-UHFFFAOYSA-N 0.000 claims description 2
- SCFSNXLXTYMORX-UHFFFAOYSA-N 3-[hydroxy(3-thiophen-3-ylpropyl)phosphoryl]-2-phenyloctanoic acid Chemical compound C1=CSC=C1CCCP(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=C1 SCFSNXLXTYMORX-UHFFFAOYSA-N 0.000 claims description 2
- DDKJIBATOKVVHU-UHFFFAOYSA-N 3-[hydroxy(4-naphthalen-1-ylbutyl)phosphoryl]-2-phenyloctanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1CCCCP(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=C1 DDKJIBATOKVVHU-UHFFFAOYSA-N 0.000 claims description 2
- CTNUDPDLOKTGLM-UHFFFAOYSA-N 3-[hydroxy(4-naphthalen-2-ylbutyl)phosphoryl]-2-phenylnonanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CCCCP(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=CC=C1 CTNUDPDLOKTGLM-UHFFFAOYSA-N 0.000 claims description 2
- NGNBFWVEFUOPBD-UHFFFAOYSA-N 3-[hydroxy(4-phenylbutyl)phosphoryl]-2-phenylhex-4-enoic acid Chemical compound C=1C=CC=CC=1CCCCP(O)(=O)C(C=CC)C(C(O)=O)C1=CC=CC=C1 NGNBFWVEFUOPBD-UHFFFAOYSA-N 0.000 claims description 2
- JQGFMMDZNWIQAO-UHFFFAOYSA-N 3-[hydroxy(methyl)phosphoryl]-2-phenylpentanoic acid Chemical compound CCC(P(C)(O)=O)C(C(O)=O)C1=CC=CC=C1 JQGFMMDZNWIQAO-UHFFFAOYSA-N 0.000 claims description 2
- DEMQVTJWNCLASY-UHFFFAOYSA-N 3-[hydroxy(naphthalen-1-yl)phosphoryl]-2-phenyloctanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1P(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=C1 DEMQVTJWNCLASY-UHFFFAOYSA-N 0.000 claims description 2
- GRDZJWYIBJPBKY-UHFFFAOYSA-N 3-[hydroxy(naphthalen-2-yl)phosphoryl]-2-phenylnonanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1P(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=CC=C1 GRDZJWYIBJPBKY-UHFFFAOYSA-N 0.000 claims description 2
- XOMWCNGREKFRHT-UHFFFAOYSA-N 3-[hydroxy(naphthalen-2-ylmethyl)phosphoryl]-2-phenylbutanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CP(O)(=O)C(C)C(C(O)=O)C1=CC=CC=C1 XOMWCNGREKFRHT-UHFFFAOYSA-N 0.000 claims description 2
- URAJLVJWLVAUHN-UHFFFAOYSA-N 3-[hydroxy(oxolan-2-yl)phosphoryl]-2-phenylnonanoic acid Chemical compound C1CCOC1P(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=CC=C1 URAJLVJWLVAUHN-UHFFFAOYSA-N 0.000 claims description 2
- PXFKTYDHSMJAIM-UHFFFAOYSA-N 3-[hydroxy(oxolan-2-ylmethyl)phosphoryl]-2-phenylpentanoic acid Chemical compound C1CCOC1CP(O)(=O)C(CC)C(C(O)=O)C1=CC=CC=C1 PXFKTYDHSMJAIM-UHFFFAOYSA-N 0.000 claims description 2
- KHUVFDZAQNSRAU-UHFFFAOYSA-N 3-[hydroxy(phenyl)phosphoryl]-2,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(P(O)(=O)C=1C=CC=CC=1)C1=CC=CC=C1 KHUVFDZAQNSRAU-UHFFFAOYSA-N 0.000 claims description 2
- OYBJLXWDRQVFIM-UHFFFAOYSA-N 3-[hydroxy(phenyl)phosphoryl]-3-methyl-2-phenylheptanoic acid Chemical compound C=1C=CC=CC=1P(O)(=O)C(C)(CCCC)C(C(O)=O)C1=CC=CC=C1 OYBJLXWDRQVFIM-UHFFFAOYSA-N 0.000 claims description 2
- YDUQPSMHPMZKTR-UHFFFAOYSA-N 3-[hydroxy(propyl)phosphoryl]-2-phenylhex-5-enoic acid Chemical compound CCCP(O)(=O)C(CC=C)C(C(O)=O)C1=CC=CC=C1 YDUQPSMHPMZKTR-UHFFFAOYSA-N 0.000 claims description 2
- CNAXODRNDBZOEK-UHFFFAOYSA-N 3-[hydroxy(pyridin-2-yl)phosphoryl]-2-phenylhex-4-enoic acid Chemical compound C=1C=CC=NC=1P(O)(=O)C(C=CC)C(C(O)=O)C1=CC=CC=C1 CNAXODRNDBZOEK-UHFFFAOYSA-N 0.000 claims description 2
- CUMUDPHIYWXSAL-UHFFFAOYSA-N 3-[hydroxy(pyridin-3-yl)phosphoryl]-4,4-dimethyl-2-phenylpentanoic acid Chemical compound C=1C=CN=CC=1P(O)(=O)C(C(C)(C)C)C(C(O)=O)C1=CC=CC=C1 CUMUDPHIYWXSAL-UHFFFAOYSA-N 0.000 claims description 2
- GSWSLLOPSSVHNH-UHFFFAOYSA-N 3-[hydroxy(pyridin-3-ylmethyl)phosphoryl]-2-phenyloctanoic acid Chemical compound C=1C=CN=CC=1CP(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=C1 GSWSLLOPSSVHNH-UHFFFAOYSA-N 0.000 claims description 2
- KGHMTMNLFRBUHA-UHFFFAOYSA-N 3-[hydroxy(pyridin-4-yl)phosphoryl]-2-phenyloctanoic acid Chemical compound C=1C=NC=CC=1P(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=C1 KGHMTMNLFRBUHA-UHFFFAOYSA-N 0.000 claims description 2
- VJUFWVJAXXPENE-UHFFFAOYSA-N 3-[hydroxy(pyridin-4-ylmethyl)phosphoryl]-2-phenylnonanoic acid Chemical compound C=1C=NC=CC=1CP(O)(=O)C(CCCCCC)C(C(O)=O)C1=CC=CC=C1 VJUFWVJAXXPENE-UHFFFAOYSA-N 0.000 claims description 2
- RLLAJZYMKRPAFD-UHFFFAOYSA-N 3-[hydroxy(thiophen-2-yl)phosphoryl]-2-phenylhexanoic acid Chemical compound C=1C=CSC=1P(O)(=O)C(CCC)C(C(O)=O)C1=CC=CC=C1 RLLAJZYMKRPAFD-UHFFFAOYSA-N 0.000 claims description 2
- DQBRDJGSHRRSHA-UHFFFAOYSA-N 3-[hydroxy(thiophen-3-yl)phosphoryl]-2-phenylhex-5-enoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(CC=C)P(O)(=O)C=1C=CSC=1 DQBRDJGSHRRSHA-UHFFFAOYSA-N 0.000 claims description 2
- GXLFEKGIXXFUDU-UHFFFAOYSA-N 3-[hydroxy(thiophen-3-yl)phosphoryl]-4,4-dimethyl-2-phenylpentanoic acid Chemical compound C1=CSC=C1P(O)(=O)C(C(C)(C)C)C(C(O)=O)C1=CC=CC=C1 GXLFEKGIXXFUDU-UHFFFAOYSA-N 0.000 claims description 2
- ROEKPAKBPRKICJ-UHFFFAOYSA-N 3-[hydroxy(thiophen-3-ylmethyl)phosphoryl]-2-phenylhex-4-enoic acid Chemical compound C1=CSC=C1CP(O)(=O)C(C=CC)C(C(O)=O)C1=CC=CC=C1 ROEKPAKBPRKICJ-UHFFFAOYSA-N 0.000 claims description 2
- GBWVWXAHISTZAM-UHFFFAOYSA-N 3-[hydroxy(thiophen-3-ylmethyl)phosphoryl]-2-phenylhexanoic acid Chemical compound C1=CSC=C1CP(O)(=O)C(CCC)C(C(O)=O)C1=CC=CC=C1 GBWVWXAHISTZAM-UHFFFAOYSA-N 0.000 claims description 2
- ODYCVZIRSDDWQP-UHFFFAOYSA-N 3-[hydroxy-[3-(1h-indol-3-yl)propyl]phosphoryl]-2-phenylbutanoic acid Chemical compound C=1NC2=CC=CC=C2C=1CCCP(O)(=O)C(C)C(C(O)=O)C1=CC=CC=C1 ODYCVZIRSDDWQP-UHFFFAOYSA-N 0.000 claims description 2
- FJNUHXVFGVUUHO-UHFFFAOYSA-N 3-fluoro-3-[hydroxy(oxolan-2-yl)phosphoryl]-2-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(F)P(O)(=O)C1CCCO1 FJNUHXVFGVUUHO-UHFFFAOYSA-N 0.000 claims description 2
- IZGVMCRCHSQIMO-UHFFFAOYSA-N 3-fluoro-3-[hydroxy(pyridin-4-ylmethyl)phosphoryl]-2-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(F)P(O)(=O)CC1=CC=NC=C1 IZGVMCRCHSQIMO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- ZZKZHDXSJLJUJO-UHFFFAOYSA-N 3-tert-butyl-3-[hydroxy(1h-indol-2-yl)phosphoryl]-2-phenylnonanoic acid Chemical compound C=1C2=CC=CC=C2NC=1P(O)(=O)C(CCCCCC)(C(C)(C)C)C(C(O)=O)C1=CC=CC=C1 ZZKZHDXSJLJUJO-UHFFFAOYSA-N 0.000 claims description 2
- BNFPBBFHQFBNPI-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2,5-dimethyl-4-naphthalen-2-ylhexanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(CC(C)C(O)=O)C(C)(C)P(O)(=O)CC1=CC=CC=C1 BNFPBBFHQFBNPI-UHFFFAOYSA-N 0.000 claims description 2
- PSDLNQPHTBAXNG-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2,5-dimethyl-4-phenyldecanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C)(CCCCC)C(CC(C)C(O)=O)C1=CC=CC=C1 PSDLNQPHTBAXNG-UHFFFAOYSA-N 0.000 claims description 2
- AFNUFQIWRPEMDB-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2-methyl-4-(oxolan-2-yl)decanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCC)C(CC(C)C(O)=O)C1CCCO1 AFNUFQIWRPEMDB-UHFFFAOYSA-N 0.000 claims description 2
- ARPKCHYSIYIVEP-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2-methyl-4-naphthalen-1-yl-5-phenylhexanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(CC(C)C(O)=O)C(C)(P(O)(=O)CC=1C=CC=CC=1)C1=CC=CC=C1 ARPKCHYSIYIVEP-UHFFFAOYSA-N 0.000 claims description 2
- YRQFDYZTQBNHIH-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2-methyl-4-naphthalen-1-yldecanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(CC(C)C(O)=O)C(CCCCC)P(O)(=O)CC1=CC=CC=C1 YRQFDYZTQBNHIH-UHFFFAOYSA-N 0.000 claims description 2
- GKDPQMZGKPKCKU-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2-methyl-4-naphthalen-2-ylundecanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(CC(C)C(O)=O)C(CCCCCC)P(O)(=O)CC1=CC=CC=C1 GKDPQMZGKPKCKU-UHFFFAOYSA-N 0.000 claims description 2
- OQICGSMDIVQSLO-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2-methyl-4-phenylhept-4-enoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CC)=C(CC(C)C(O)=O)C1=CC=CC=C1 OQICGSMDIVQSLO-UHFFFAOYSA-N 0.000 claims description 2
- GYTUBYBAFVSSNE-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2-methyl-4-pyridin-3-yloctanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCC)C(CC(C)C(O)=O)C1=CC=CN=C1 GYTUBYBAFVSSNE-UHFFFAOYSA-N 0.000 claims description 2
- TYUCIABADKZDNA-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-4-(1h-indol-3-yl)-2-methyloctanoic acid Chemical compound C=1NC2=CC=CC=C2C=1C(CC(C)C(O)=O)C(CCC)P(O)(=O)CC1=CC=CC=C1 TYUCIABADKZDNA-UHFFFAOYSA-N 0.000 claims description 2
- CSXRKJJCEXAKML-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-5-fluoro-2-methyl-4-naphthalen-2-ylpentanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(CC(C)C(O)=O)C(F)P(O)(=O)CC1=CC=CC=C1 CSXRKJJCEXAKML-UHFFFAOYSA-N 0.000 claims description 2
- DSVTVEQSKWCKOI-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-5-tert-butyl-2-methyl-4-thiophen-3-yldecanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCC)(C(C)(C)C)C(CC(C)C(O)=O)C=1C=CSC=1 DSVTVEQSKWCKOI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- KGLGRTWZGKFTCK-UHFFFAOYSA-N 2-[1-[(4-fluorophenyl)-hydroxyphosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)C1=CC=C(F)C=C1 KGLGRTWZGKFTCK-UHFFFAOYSA-N 0.000 claims 1
- IBRZZPYVALISRO-UHFFFAOYSA-N 2-[1-[cyclohexyl(hydroxy)phosphoryl]pentyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCCC)P(O)(=O)C1CCCCC1 IBRZZPYVALISRO-UHFFFAOYSA-N 0.000 claims 1
- QEVAQIOYUYQTKA-UHFFFAOYSA-N 2-[1-[hydroxy(3-naphthalen-2-ylpropyl)phosphoryl]hexyl]pentanedioic acid Chemical compound C1=CC=CC2=CC(CCCP(O)(=O)C(C(CCC(O)=O)C(O)=O)CCCCC)=CC=C21 QEVAQIOYUYQTKA-UHFFFAOYSA-N 0.000 claims 1
- UCJCRRHPWOSSRO-UHFFFAOYSA-N 2-[1-[hydroxy(3-thiophen-3-ylpropyl)phosphoryl]but-2-enyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C=CC)P(O)(=O)CCCC=1C=CSC=1 UCJCRRHPWOSSRO-UHFFFAOYSA-N 0.000 claims 1
- YONJNJZDOBGXQA-UHFFFAOYSA-N 2-[1-[hydroxy(naphthalen-2-ylmethyl)phosphoryl]ethyl]pentanedioic acid Chemical compound C1=CC=CC2=CC(CP(O)(=O)C(C(CCC(O)=O)C(O)=O)C)=CC=C21 YONJNJZDOBGXQA-UHFFFAOYSA-N 0.000 claims 1
- BRMQLMQKNRLEOM-UHFFFAOYSA-N 2-[1-[hydroxy-[(4-methylphenyl)methyl]phosphoryl]butyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCC)P(O)(=O)CC1=CC=C(C)C=C1 BRMQLMQKNRLEOM-UHFFFAOYSA-N 0.000 claims 1
- LELHEMVPYWANHT-UHFFFAOYSA-N 2-[[benzyl(hydroxy)phosphoryl]-phenylmethyl]pentanedioic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C(CCC(=O)O)C(O)=O)C1=CC=CC=C1 LELHEMVPYWANHT-UHFFFAOYSA-N 0.000 claims 1
- NNOORYMCDHHFIF-UHFFFAOYSA-N 2-[[hydroxy(naphthalen-1-yl)phosphoryl]-phenylmethyl]pentanedioic acid Chemical compound C=1C=CC2=CC=CC=C2C=1P(O)(=O)C(C(CCC(=O)O)C(O)=O)C1=CC=CC=C1 NNOORYMCDHHFIF-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- OYDNDEUPVMVDKF-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2,4,4-trimethyl-2-thiophen-3-ylpentanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(C(C)(C)C)C(C)(C(O)=O)C=1C=CSC=1 OYDNDEUPVMVDKF-UHFFFAOYSA-N 0.000 claims 1
- YWWYDHRKVBGTJI-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-ethylheptanoic acid Chemical compound CCCCC(C(CC)C(O)=O)P(O)(=O)CC1=CC=CC=C1 YWWYDHRKVBGTJI-UHFFFAOYSA-N 0.000 claims 1
- UDASHXDTCYHGTF-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-3-phenyl-2-pyridin-4-ylpropanoic acid Chemical compound C=1C=NC=CC=1C(C(=O)O)C(P(O)(=O)CC=1C=CC=CC=1)C1=CC=CC=C1 UDASHXDTCYHGTF-UHFFFAOYSA-N 0.000 claims 1
- GUOIXFKKEFVPIT-UHFFFAOYSA-N 3-[hydroxy(1h-indol-2-ylmethyl)phosphoryl]-4,4-dimethyl-2-phenylpentanoic acid Chemical compound C=1C2=CC=CC=C2NC=1CP(O)(=O)C(C(C)(C)C)C(C(O)=O)C1=CC=CC=C1 GUOIXFKKEFVPIT-UHFFFAOYSA-N 0.000 claims 1
- LGUWXXIWTBKTHA-UHFFFAOYSA-N 3-[hydroxy(3-naphthalen-2-ylpropyl)phosphoryl]-2-phenylheptanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CCCP(O)(=O)C(CCCC)C(C(O)=O)C1=CC=CC=C1 LGUWXXIWTBKTHA-UHFFFAOYSA-N 0.000 claims 1
- HCEHRLLZMQVNRS-UHFFFAOYSA-N 3-[hydroxy(naphthalen-1-ylmethyl)phosphoryl]-3-methyl-2-phenyloctanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1CP(O)(=O)C(C)(CCCCC)C(C(O)=O)C1=CC=CC=C1 HCEHRLLZMQVNRS-UHFFFAOYSA-N 0.000 claims 1
- FXROVTMTDUXAPH-UHFFFAOYSA-N 3-[hydroxy(pyridin-2-ylmethyl)phosphoryl]-4,4-dimethyl-2-phenylpentanoic acid Chemical compound C=1C=CC=NC=1CP(O)(=O)C(C(C)(C)C)C(C(O)=O)C1=CC=CC=C1 FXROVTMTDUXAPH-UHFFFAOYSA-N 0.000 claims 1
- XPHSWSPJUMQEIH-UHFFFAOYSA-N 3-[hydroxy-[3-(oxolan-2-yl)propyl]phosphoryl]-2-phenylhex-5-enoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(CC=C)P(O)(=O)CCCC1CCCO1 XPHSWSPJUMQEIH-UHFFFAOYSA-N 0.000 claims 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- KAMAGUHTEQIQIA-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2-methyl-4-phenylnonanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCC)C(CC(C)C(O)=O)C1=CC=CC=C1 KAMAGUHTEQIQIA-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract description 89
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 abstract description 89
- 206010060862 Prostate cancer Diseases 0.000 abstract description 40
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 37
- 230000012010 growth Effects 0.000 abstract description 13
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 208000017497 prostate disease Diseases 0.000 abstract description 10
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract description 2
- 229940127422 Dipeptidase Inhibitors Drugs 0.000 abstract 1
- 150000008298 phosphoramidates Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
- 238000011282 treatment Methods 0.000 description 91
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 206010061289 metastatic neoplasm Diseases 0.000 description 50
- 230000001394 metastastic effect Effects 0.000 description 49
- 230000000683 nonmetastatic effect Effects 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 235000019439 ethyl acetate Nutrition 0.000 description 38
- ISEYJGQFXSTPMQ-UHFFFAOYSA-N 2-(phosphonomethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(O)=O ISEYJGQFXSTPMQ-UHFFFAOYSA-N 0.000 description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000007788 liquid Substances 0.000 description 30
- 229910001868 water Inorganic materials 0.000 description 28
- 238000005481 NMR spectroscopy Methods 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000007924 injection Substances 0.000 description 23
- 238000002347 injection Methods 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 238000001356 surgical procedure Methods 0.000 description 18
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000012230 colorless oil Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 230000004565 tumor cell growth Effects 0.000 description 11
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 10
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 125000001931 aliphatic group Chemical group 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- ACXSUJZCYZEUIF-UHFFFAOYSA-N dibenzyl 2-methylidenepentanedioate Chemical compound C=1C=CC=CC=1COC(=O)C(=C)CCC(=O)OCC1=CC=CC=C1 ACXSUJZCYZEUIF-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 229930195712 glutamate Natural products 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- PHIBEYMUALDAQI-UHFFFAOYSA-N benzylphosphinic acid Chemical compound OP(=O)CC1=CC=CC=C1 PHIBEYMUALDAQI-UHFFFAOYSA-N 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 208000037819 metastatic cancer Diseases 0.000 description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- WBTADCUPRLXNGJ-UHFFFAOYSA-N [hydroxy(phenyl)methyl]-(1-oxo-2-phenyl-1-phenylmethoxyhexan-2-yl)phosphinic acid Chemical compound C(C1=CC=CC=C1)OC(=O)C(C1=CC=CC=C1)(P(O)(=O)C(C1=CC=CC=C1)O)CCCC WBTADCUPRLXNGJ-UHFFFAOYSA-N 0.000 description 5
- 235000019445 benzyl alcohol Nutrition 0.000 description 5
- OAXIRHXXAWQAFS-UHFFFAOYSA-N benzyl-(5-oxo-5-phenylmethoxy-2-phenylmethoxycarbonylpentyl)phosphinic acid Chemical compound C=1C=CC=CC=1CP(=O)(O)CC(C(=O)OCC=1C=CC=CC=1)CCC(=O)OCC1=CC=CC=C1 OAXIRHXXAWQAFS-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000002679 ablation Methods 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 238000007080 aromatic substitution reaction Methods 0.000 description 4
- NVZRFUCVCIVKJR-UHFFFAOYSA-N benzyl(methoxy)phosphinic acid Chemical compound COP(O)(=O)CC1=CC=CC=C1 NVZRFUCVCIVKJR-UHFFFAOYSA-N 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 125000006178 methyl benzyl group Chemical group 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000023958 prostate neoplasm Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- NNCRKIKXRSDRFI-UHFFFAOYSA-N 2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CC1=CC=CC=C1 NNCRKIKXRSDRFI-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000011581 secondary neoplasm Diseases 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 238000011277 treatment modality Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LZLYJQVFORDMDW-UHFFFAOYSA-N (5-oxo-5-phenylmethoxy-2-phenylmethoxycarbonylpentyl)phosphinic acid Chemical compound C=1C=CC=CC=1COC(=O)C(CP(=O)O)CCC(=O)OCC1=CC=CC=C1 LZLYJQVFORDMDW-UHFFFAOYSA-N 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- XOQVDBCNWPUEPS-UHFFFAOYSA-N 2-(phosphonomethyl)butanedioic acid Chemical compound OC(=O)CC(C(O)=O)CP(O)(O)=O XOQVDBCNWPUEPS-UHFFFAOYSA-N 0.000 description 2
- VAZDQVAVNHZARH-UHFFFAOYSA-N 2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CCCC1=CC=CC=C1 VAZDQVAVNHZARH-UHFFFAOYSA-N 0.000 description 2
- CAGAVCIHAJPIJR-UHFFFAOYSA-N 2-[[hydroxy(methyl)phosphoryl]methyl]pentanedioic acid Chemical compound CP(O)(=O)CC(C(O)=O)CCC(O)=O CAGAVCIHAJPIJR-UHFFFAOYSA-N 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
- CWNNYYIZGGDCHS-UHFFFAOYSA-N 2-methylideneglutaric acid Chemical compound OC(=O)CCC(=C)C(O)=O CWNNYYIZGGDCHS-UHFFFAOYSA-N 0.000 description 2
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- MTWVYGIIHVUGNL-UHFFFAOYSA-N CCCCP(O)=O Chemical compound CCCCP(O)=O MTWVYGIIHVUGNL-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 2
- 206010025538 Malignant ascites Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 2
- 206010071019 Prostatic dysplasia Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- WUSOIHPNXFCZDU-UHFFFAOYSA-N butyl-(5-oxo-5-phenylmethoxy-2-phenylmethoxycarbonylpentyl)phosphinic acid Chemical compound C=1C=CC=CC=1COC(=O)C(CP(O)(=O)CCCC)CCC(=O)OCC1=CC=CC=C1 WUSOIHPNXFCZDU-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000000315 cryotherapy Methods 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 2
- OSEXMMDMNNQLFC-UHFFFAOYSA-O hydroxy-oxo-(2-phenylethyl)phosphanium Chemical compound O[P+](=O)CCC1=CC=CC=C1 OSEXMMDMNNQLFC-UHFFFAOYSA-O 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000006959 non-competitive inhibition Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 2
- 210000004908 prostatic fluid Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 2
- 229940006509 strontium-89 Drugs 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 2
- 230000006967 uncompetitive inhibition Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- FHHWULUOLYCQTI-UHFFFAOYSA-N (5-oxo-5-phenylmethoxy-2-phenylmethoxycarbonylpentyl)-(2-phenylethyl)phosphinic acid Chemical compound C=1C=CC=CC=1COC(=O)CCC(C(=O)OCC=1C=CC=CC=1)CP(=O)(O)CCC1=CC=CC=C1 FHHWULUOLYCQTI-UHFFFAOYSA-N 0.000 description 1
- PAMOVZQBFHPKDL-UHFFFAOYSA-N (5-oxo-5-phenylmethoxy-2-phenylmethoxycarbonylpentyl)-(3-phenylpropyl)phosphinic acid Chemical compound C=1C=CC=CC=1COC(=O)CCC(C(=O)OCC=1C=CC=CC=1)CP(=O)(O)CCCC1=CC=CC=C1 PAMOVZQBFHPKDL-UHFFFAOYSA-N 0.000 description 1
- ODKKBCHDKMQNSO-UHFFFAOYSA-N (5-oxo-5-phenylmethoxypentyl)-(2-phenylethyl)phosphinic acid Chemical compound C=1C=CC=CC=1CCP(=O)(O)CCCCC(=O)OCC1=CC=CC=C1 ODKKBCHDKMQNSO-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GBWJRXCXCSVTQG-UHFFFAOYSA-N 2-(2-phosphonopent-4-enyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(P(O)(O)=O)CC=C GBWJRXCXCSVTQG-UHFFFAOYSA-N 0.000 description 1
- PBMSCTOYRUARSI-UHFFFAOYSA-N 2-[1-[(4-fluorophenyl)methyl-hydroxyphosphoryl]pentyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCCC)P(O)(=O)CC1=CC=C(F)C=C1 PBMSCTOYRUARSI-UHFFFAOYSA-N 0.000 description 1
- PGXLVXCPSHLUKS-UHFFFAOYSA-N 2-[1-[benzyl(hydroxy)phosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)CC1=CC=CC=C1 PGXLVXCPSHLUKS-UHFFFAOYSA-N 0.000 description 1
- LTZUNMJTYGQNBK-UHFFFAOYSA-N 2-[1-[ethyl(hydroxy)phosphoryl]propyl]pentanedioic acid Chemical compound CCP(O)(=O)C(CC)C(C(O)=O)CCC(O)=O LTZUNMJTYGQNBK-UHFFFAOYSA-N 0.000 description 1
- ALCPTIIURRAAND-UHFFFAOYSA-N 2-[1-[hydroxy(1h-indol-2-ylmethyl)phosphoryl]butyl]pentanedioic acid Chemical compound C1=CC=C2NC(CP(O)(=O)C(C(CCC(O)=O)C(O)=O)CCC)=CC2=C1 ALCPTIIURRAAND-UHFFFAOYSA-N 0.000 description 1
- SJNQPIMXBCOMMF-UHFFFAOYSA-N 2-[1-[hydroxy(2-phenylethyl)phosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(C)P(O)(=O)CCC1=CC=CC=C1 SJNQPIMXBCOMMF-UHFFFAOYSA-N 0.000 description 1
- DAHDVVMZEBNNCX-UHFFFAOYSA-N 2-[1-[hydroxy(4-phenylbutyl)phosphoryl]butyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCC)P(O)(=O)CCCCC1=CC=CC=C1 DAHDVVMZEBNNCX-UHFFFAOYSA-N 0.000 description 1
- LYNIUGOOSVAYEE-UHFFFAOYSA-N 2-[1-[hydroxy(naphthalen-1-yl)phosphoryl]heptyl]pentanedioic acid Chemical compound C1=CC=C2C(P(O)(=O)C(C(CCC(O)=O)C(O)=O)CCCCCC)=CC=CC2=C1 LYNIUGOOSVAYEE-UHFFFAOYSA-N 0.000 description 1
- HARSBRQBBDBBDE-UHFFFAOYSA-N 2-[1-[hydroxy(naphthalen-2-ylmethyl)phosphoryl]propyl]pentanedioic acid Chemical compound C1=CC=CC2=CC(CP(O)(=O)C(C(CCC(O)=O)C(O)=O)CC)=CC=C21 HARSBRQBBDBBDE-UHFFFAOYSA-N 0.000 description 1
- LZSLZZSZOYSMHQ-UHFFFAOYSA-N 2-[1-[hydroxy(phenyl)phosphoryl]butyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCC)P(O)(=O)C1=CC=CC=C1 LZSLZZSZOYSMHQ-UHFFFAOYSA-N 0.000 description 1
- QKKQOASRUISMLV-UHFFFAOYSA-N 2-[1-[hydroxy(thiophen-3-yl)phosphoryl]propyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CC)P(O)(=O)C=1C=CSC=1 QKKQOASRUISMLV-UHFFFAOYSA-N 0.000 description 1
- MGZOENIFEFYLKT-UHFFFAOYSA-N 2-[1-[hydroxy-[(4-methoxyphenyl)methyl]phosphoryl]pentyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCCC)P(O)(=O)CC1=CC=C(OC)C=C1 MGZOENIFEFYLKT-UHFFFAOYSA-N 0.000 description 1
- ZCIUJTQADZXCRD-UHFFFAOYSA-N 2-[1-[hydroxy-[(4-methylphenyl)methyl]phosphoryl]but-3-enyl]pentanedioic acid Chemical compound CC1=CC=C(CP(O)(=O)C(CC=C)C(CCC(O)=O)C(O)=O)C=C1 ZCIUJTQADZXCRD-UHFFFAOYSA-N 0.000 description 1
- XGZPMDKVCVBMGK-UHFFFAOYSA-N 2-[1-[hydroxy-[3-(1h-indol-3-yl)propyl]phosphoryl]heptyl]pentanedioic acid Chemical compound C1=CC=C2C(CCCP(O)(=O)C(C(CCC(O)=O)C(O)=O)CCCCCC)=CNC2=C1 XGZPMDKVCVBMGK-UHFFFAOYSA-N 0.000 description 1
- WWTCPEIKKSZUBC-UHFFFAOYSA-N 2-[1-[hydroxy-[[3-(trifluoromethyl)phenyl]methyl]phosphoryl]pentyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)C(CCCC)P(O)(=O)CC1=CC=CC(C(F)(F)F)=C1 WWTCPEIKKSZUBC-UHFFFAOYSA-N 0.000 description 1
- FRHVGKONVMDASL-UHFFFAOYSA-N 2-[2-[(4-fluorophenyl)-hydroxyphosphoryl]ethyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCP(O)(=O)C1=CC=C(F)C=C1 FRHVGKONVMDASL-UHFFFAOYSA-N 0.000 description 1
- MIINQJNPWDYQGB-UHFFFAOYSA-N 2-[[butyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound CCCCP(O)(=O)CC(C(O)=O)CCC(O)=O MIINQJNPWDYQGB-UHFFFAOYSA-N 0.000 description 1
- ZETADZSPCOHVMK-UHFFFAOYSA-N 2-[[hydroxy(naphthalen-2-yl)phosphoryl]-phenylmethyl]pentanedioic acid Chemical compound C=1C=C2C=CC=CC2=CC=1P(O)(=O)C(C(CCC(=O)O)C(O)=O)C1=CC=CC=C1 ZETADZSPCOHVMK-UHFFFAOYSA-N 0.000 description 1
- OPPRXRUWIWTMDJ-UHFFFAOYSA-N 2-[fluoro-[hydroxy(naphthalen-1-yl)phosphoryl]methyl]pentanedioic acid Chemical compound C1=CC=C2C(P(O)(=O)C(F)C(CCC(=O)O)C(O)=O)=CC=CC2=C1 OPPRXRUWIWTMDJ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- WZMOEYCPWHIRPE-UHFFFAOYSA-N 2-methyl-2-(oxolan-2-yl)propanoic acid Chemical compound OC(=O)C(C)(C)C1CCCO1 WZMOEYCPWHIRPE-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XBYMHRQZWNXAPB-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-(2-thiophen-3-ylethyl)nonanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCCC)C(C(O)=O)CCC=1C=CSC=1 XBYMHRQZWNXAPB-UHFFFAOYSA-N 0.000 description 1
- DBKRRWXUATXNRX-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-ethyl-4,4-dimethylpentanoic acid Chemical compound CCC(C(O)=O)C(C(C)(C)C)P(O)(=O)CC1=CC=CC=C1 DBKRRWXUATXNRX-UHFFFAOYSA-N 0.000 description 1
- LRFCGUDNPOGIQI-UHFFFAOYSA-N 3-[benzyl(hydroxy)phosphoryl]-2-methyl-2-thiophen-3-yloctanoic acid Chemical compound C=1C=CC=CC=1CP(O)(=O)C(CCCCC)C(C)(C(O)=O)C=1C=CSC=1 LRFCGUDNPOGIQI-UHFFFAOYSA-N 0.000 description 1
- AJTGQBGSPWDDRY-UHFFFAOYSA-N 3-[hydroxy(1H-indol-2-ylmethyl)phosphoryl]-2-phenylheptanoic acid Chemical compound N1C(=CC2=CC=CC=C12)CP(=O)(C(C(C(=O)O)C1=CC=CC=C1)CCCC)O AJTGQBGSPWDDRY-UHFFFAOYSA-N 0.000 description 1
- VPVWDBJYNBTJBJ-UHFFFAOYSA-N 3-[hydroxy(1h-indol-3-ylmethyl)phosphoryl]-2-phenyloctanoic acid Chemical compound C=1NC2=CC=CC=C2C=1CP(O)(=O)C(CCCCC)C(C(O)=O)C1=CC=CC=C1 VPVWDBJYNBTJBJ-UHFFFAOYSA-N 0.000 description 1
- GQFISTVUYXTLIP-UHFFFAOYSA-N 3-[hydroxy(2-naphthalen-1-ylethyl)phosphoryl]-3-methyl-2-phenyloctanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1CCP(O)(=O)C(C)(CCCCC)C(C(O)=O)C1=CC=CC=C1 GQFISTVUYXTLIP-UHFFFAOYSA-N 0.000 description 1
- BKHMWYFAXKEGDE-UHFFFAOYSA-N 3-[hydroxy(2-phenylethyl)phosphoryl]-2-phenylpentanoic acid Chemical compound C=1C=CC=CC=1CCP(O)(=O)C(CC)C(C(O)=O)C1=CC=CC=C1 BKHMWYFAXKEGDE-UHFFFAOYSA-N 0.000 description 1
- JOENJCAISRIQQQ-UHFFFAOYSA-N 3-[hydroxy(3-naphthalen-2-ylpropyl)phosphoryl]-4,4-dimethyl-2-phenylpentanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CCCP(O)(=O)C(C(C)(C)C)C(C(O)=O)C1=CC=CC=C1 JOENJCAISRIQQQ-UHFFFAOYSA-N 0.000 description 1
- BWCMSJVIBOAOIC-UHFFFAOYSA-N 3-[hydroxy(pyridin-2-ylmethyl)phosphoryl]-2-phenylheptanoic acid Chemical compound C=1C=CC=NC=1CP(O)(=O)C(CCCC)C(C(O)=O)C1=CC=CC=C1 BWCMSJVIBOAOIC-UHFFFAOYSA-N 0.000 description 1
- LRYNEROBYFMNJC-UHFFFAOYSA-N 3-[hydroxy(thiophen-2-ylmethyl)phosphoryl]-2-phenylpentanoic acid Chemical compound C=1C=CSC=1CP(O)(=O)C(CC)C(C(O)=O)C1=CC=CC=C1 LRYNEROBYFMNJC-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- OFKQZANSWRMVIS-UHFFFAOYSA-N 5-[benzyl(hydroxy)phosphoryl]-2,6,6-trimethyl-4-phenylheptanoic acid Chemical compound C=1C=CC=CC=1C(CC(C)C(O)=O)C(C(C)(C)C)P(O)(=O)CC1=CC=CC=C1 OFKQZANSWRMVIS-UHFFFAOYSA-N 0.000 description 1
- WRSDJJXJDSEUSQ-UHFFFAOYSA-N 5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)CCCC(=O)OCC1=CC=CC=C1 WRSDJJXJDSEUSQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- GVPIUBYPNJRTQD-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)C(C1=CC=CC=C1)P(O)(=O)CCCC Chemical compound C(C1=CC=CC=C1)OC(=O)C(C1=CC=CC=C1)P(O)(=O)CCCC GVPIUBYPNJRTQD-UHFFFAOYSA-N 0.000 description 1
- KDHUHPMQUROTOM-UHFFFAOYSA-N C(CCCCCC)(=O)O.S(=O)(=O)(O)O.C(CCCCCC)(=O)O Chemical compound C(CCCCCC)(=O)O.S(=O)(=O)(O)O.C(CCCCCC)(=O)O KDHUHPMQUROTOM-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 206010068116 Metastatic uterine cancer Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108010090363 N-acetylaspartyl-beta-linked glutamate Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029301 Neurological disorders of the eye Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- QUPGZWKXSBQKEE-UHFFFAOYSA-N OP(=O)CCCC1=CC=CC=C1 Chemical compound OP(=O)CCCC1=CC=CC=C1 QUPGZWKXSBQKEE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JHUYNQGHNWXETM-UHFFFAOYSA-M [Br-].[Mg+]CCCC1=CC=CC=C1 Chemical compound [Br-].[Mg+]CCCC1=CC=CC=C1 JHUYNQGHNWXETM-UHFFFAOYSA-M 0.000 description 1
- AQQVTZBWWYVEGR-UHFFFAOYSA-N [NH4+].[O-][PH2]=O Chemical compound [NH4+].[O-][PH2]=O AQQVTZBWWYVEGR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical compound C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 1
- DMBLKETZCXYUQQ-UHFFFAOYSA-N benzyl-[(4-methylphenyl)methoxy]phosphinic acid Chemical compound C1=CC(C)=CC=C1COP(O)(=O)CC1=CC=CC=C1 DMBLKETZCXYUQQ-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- TXHWYSOQHNMOOU-UHFFFAOYSA-N chloro(diethoxy)phosphane Chemical compound CCOP(Cl)OCC TXHWYSOQHNMOOU-UHFFFAOYSA-N 0.000 description 1
- DQTRYXANLKJLPK-UHFFFAOYSA-N chlorophosphonous acid Chemical compound OP(O)Cl DQTRYXANLKJLPK-UHFFFAOYSA-N 0.000 description 1
- 229910000151 chromium(III) phosphate Inorganic materials 0.000 description 1
- IKZBVTPSNGOVRJ-UHFFFAOYSA-K chromium(iii) phosphate Chemical compound [Cr+3].[O-]P([O-])([O-])=O IKZBVTPSNGOVRJ-UHFFFAOYSA-K 0.000 description 1
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- HCSDJECSMANTCX-UHFFFAOYSA-N dichloro(methoxy)phosphane Chemical compound COP(Cl)Cl HCSDJECSMANTCX-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 108010076560 isospaglumic acid Proteins 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 1
- OUTILEHLSPAZIN-UHFFFAOYSA-M magnesium;ethylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]CC1=CC=CC=C1 OUTILEHLSPAZIN-UHFFFAOYSA-M 0.000 description 1
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- GUCKKCMJTSNWCU-BQBZGAKWSA-N spaglumic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(=O)N[C@H](C(O)=O)CCC(O)=O GUCKKCMJTSNWCU-BQBZGAKWSA-N 0.000 description 1
- 229960000341 spaglumic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
Definitions
- the present invention relates to novel NAALADase 20 inhibitors and methods of using the same for treating cancer, preventing tumor cell growth, inhibiting prostate tumor cell growth, and inhibiting NAALADase enzyme activity, by administering an effective amount of the NAALADase inhibitor.
- Prostate cancer is the leading form of cancer and the second leading cause of death from cancer for men in the United States.
- the American Cancer Society has estimated that in 1996 alone, 317,100 new cases of prostate cancer were diagnosed and 41,400 deaths were caused by prostate cancer.
- the incidence rate of prostate cancer increased 65% between 1980 and 1990, and will continue to rise with improved screening tests and longer life expectancies. While most men used to die of other illnesses before prostate cancer had a chance to develop, higher prostate cancer mortality rates are expected as men live longer and the disease has more time to progress .
- PSMA Prostate Specific Membrane Antigen
- NAAG and NAALADase have been implicated in several human and animal pathological conditions relating to glutamate abnormalities and neurotoxicity . For example, it has been demonstrated that intra-hippocampal injections of NAAG elicit prolonged seizure activity. More recently, it was reported that rats genetically prone to epileptic seizures have a persistent increase in their basal level of NAALADase activity. These observations lend support the hypothesis that increased availability of synaptic gluta ate elevates seizure susceptibility, and suggest that NAALADase inhibitors may- provide anti-epileptic activity.
- NAAG and NAALADase have also been implicated in the pathogenesis of ALS and in the pathologically similar animal disease called Hereditary Canine Spinal Muscular Atrophy (HCSMA) . It has been shown that concentrations of NAAG and its metabolites -- NAA, glutamate and aspartate -- are elevated two- to three-fold in the cerebrospinal fluid of ALS patients and HCSMA dogs. Additionally, NAALADase activity is significantly increased (two- to three-fold) in post-mortem spinal cord tissue from ALS patients and HCSMA dogs. As such, NAALADase inhibitors might be clinically useful in curbing the progression of ALS if an increased metabolism of NAAG is responsible for the alterations of CSF levels of these acidic amino acids and peptides.
- HCSMA Hereditary Canine Spinal Muscular Atrophy
- NAALADase inhibitors could be useful in treating glutamate abnormalities.
- the present invention is directed to the surprising and unexpected discovery that the novel compounds of the present invention are not only effective NAALADase inhibitors but are effective in treating prostate diseases, particularly prostate cancer.
- the cancer data relate to prostate cancer cells, NAALADase inhibitors are expected to be equally effective in treating cancer of other tissues where NAALADase enzyme reside, such as the brain, kidney and testis.
- NAALADase inhibitors While a few NAALADase inhibitors have been identified, they have only been used in non-clinical research. Examples of such inhibitors include general metallopeptidase inhibitors such as o-phenanthroline, metal chelators such as EGTA and EDTA, and peptide analogs such as quisqualic acid and ⁇ -NAAG. Accordingly, a need exists for more NAALADase inhibitors to be identified and, particularly, for the treatment of prostate diseases such as prostate cancer.
- general metallopeptidase inhibitors such as o-phenanthroline
- metal chelators such as EGTA and EDTA
- peptide analogs such as quisqualic acid and ⁇ -NAAG. Accordingly, a need exists for more NAALADase inhibitors to be identified and, particularly, for the treatment of prostate diseases such as prostate cancer.
- the present invention is directed to novel NAALADase inhibitors and methods of using the same for treating cancer, preventing tumor cell growth, inhibiting prostate tumor cell growth, and inhibiting NAALADase enzyme activity, in an animal, comprising administering an effective amount of the NAALADase inhibitor.
- Preferred NAALADase inhibitors include compounds of formula I:
- R 2 is C x -C 9 straight or branched chain alkyl, C 2 -C 9 - straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar x ;
- R 2 is C x -C 9 straight or branched chain alkyl, C 2 -C 9 - straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar l; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl groups may be optionally substituted with carboxylic acid;
- R 3 and R. are independently hydrogen, straight or branched chain alkyl, C 2 - C 6 straight or branched chain alkenyl, dialkyl, halogen, or Arj_ provided that both R 3 and R 4 are not hydrogen.
- the compound of formula I is present in an amount that is effective for inhibiting NAALADase enzyme activity, or treating a prostate disease in an animal.
- the present invention further relates to a method of inhibiting NAALADase enzyme activity in an animal, comprising administering an effective amount of the compound of formula I to said animal .
- FIG. 1 is a bar graph plotting the growth of the prostate cancer cell line, LNCAP, against various concentrations of quisqualic acid, a NAALADase Inhibitor.
- FIG. 1 shows the effect of 7 -day treatment with quisqualate on the growth of LNCAP cells. Concentrations ranging from 10 nM to 1 ⁇ M of quisqualate show a sharp dose-dependent decrease of LNCAP cell proliferation as indicated by the significant decrease in the incorporation of [3H] thymidine .
- FIG. 2 is a bar graph plotting the growth of the prostate cancer cell line, LNCAP, against various concentrations of 2- (phosphonomethyl) pentanedioic acid, a NAALADase Inhibitor.
- FIG. 2 shows the effect of 7-day treatment with 2- (phosphonomethyl) pentanedioic acid on the growth of LNCAP cells. Concentrations ranging from 100 pM to 10 nM of 2- (phosphonomethyl) pentanedioic acid show a sharp dose-dependent decrease of LNCAP cell proliferation as indicated by the significant decrease in the incorporation of [3H] thymidine .
- FIG. 3 is a line graph of the response of LNCAP human prostate tumors to daily treatment with 2-
- FIG. 4 is a line graph plotting the survival percentage of animals treated with injections against the number of days.
- FIG. 5 is a line graph plotting tumor growth against days following rat dunning cell injections. Cells were injected, over a period of 84 days, with various dosages of 2- (phosphonomethyl) pentanedioic acid and a control vehicle. FIG. 5 shows that tumor growth slowed as a function of 2- (phosphonomethyl) pentanedioic acid dosage.
- FIG. 6 is a line graph of the response of R3327 rat prostate tumors to daily treatment with 2- [[ (phenylmethyl) hydroxyphosphinyl] methyl] pentanedioic acid. Mean of individual tumor volumes expressed relative to the volume at the start of treatment (V/V Q ) are plotted as a function of time. Treatment with 2-
- Compound 3 refers to 2 ⁇ (phosphonomethyl) pentanedioic acid, a NAALADase inhibitor.
- Competitive, uncompetitive and non-competitive inhibition can be distinguished by the effects of an inhibitor on the reaction kinetics of an enzvme .
- Competitive inhibition occurs when the inhibitor combines reversibly with the enzyme in such a way that it competes with a normal substrate for binding at the active site.
- the affinity between the inhibitor and the enzyme may be measured by the inhibitor constant, K i( which is defined as:
- [E] is the concentration of the enzyme
- [I] is the concentration of the inhibitor
- [EI] is the concentration of the enzyme-inhibitor complex formed by the reaction of the enzyme with the inhibitor.
- K ⁇ as used herein refers to the affinity between the inventive compounds and NAALADase.
- IC50 is a related term used to define the concentration or amount of a compound which is required to cause a 50% inhibition of the target enzyme.
- inhibitors in the context of tumor growth or tumor cell growth, may be assessed by delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, among others. In the extreme, complete inhibition, is referred to herein as prevention.
- NAAG refers to N-acetyl-aspartyl-glutamate, an important peptide component of the brain, with levels comparable to the major inhibitor neurotransmitter gamma- aminobutyric acid (GABA) .
- GABA neurotransmitter gamma- aminobutyric acid
- NAAG is neuron-specific, present in synaptic vesicles and released upon neuronal stimulation in several systems presumed to be glutamatergic . Studies suggest that NAAG may function as a neurotransmitter and/or neuromodulator in the central nervous system, or as a precursor of the neurotransmitter glutamate.
- NAALADase refers to N-acetylated ⁇ -linked acidic dipeptidase, a membrane-bound metallopeptidase which catabolizes NAAG to N-acetylaspartate (NAA) and glutamate:
- NAALADase shows a high affinity for NAAG with a Km of 540 nM. If NAAG is a bioactive peptide, then NAALADase may serve to inactivate NAAG'S synaptic action. Alternatively, if NAAG functions as a precursor for glutamate, the primary function of NAALADase may be to regulate synaptic glutamate availability.
- “Pharmaceutically acceptable salt” refers to a salt of the inventive compounds which possesses the desired pharmacological activity and which is neither biologically nor otherwise undesirable.
- the salt can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate butyrate, citrate, camphorate, ca phorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate heptanoate, hexanoate, hydro- chloride hydrobromide , hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, thiocyan
- Examples of a base salt include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine and lysine .
- the basic nitrogen-containing groups can be quarternized with agents including lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl , dibutyl and diamyl sulfates; long chain halides such as decyl , lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides such as benzyl and phenethyl bromides .
- lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides
- dialkyl sulfates such as dimethyl, diethyl , dibutyl and diamyl sulfates
- long chain halides such as decyl , lauryl, myristyl and ste
- prevention in relation to tumor growth or tumor cell growth, means no tumor or tumor cell growth if none had occurred, no further tumor or tumor cell growth if there had already been growth.
- prostatic disease relates to prostate cancer such as adenocarcinoma or metastatic cancers, conditions characterized by abnormal growth of prostatic epithelial cells such as benign prostatic hyperplasia, and other conditions requiring treatment by the compounds of the present invention.
- PSA refers to Prostate Specific Antigen, a well known prostate cancer marker. It is a protein produced by prostate cells and is frequently present at elevated levels in the blood of men with prostate cancer. PSA correlates with tumor burden, serves as an indicator of metastatic involvement, and provides a parameter for following a prostate cancer patient's response to surgery, irradiation and androgen replacement therapy.
- PSMA Prostate Specific Membrane Antigen
- PSMA Prostate Specific Membrane Antigen
- prostatic ductal epithelium is present in seminal plasma, prostatic fluid and urine. It has been found that the expression of PSMA cDNA confers the activity of NAALADase.
- treatment refers to any process, action, application, therapy, or the like, wherein an animal, including a human being, is subject to medical aid with the object of improving the animal's condition, directly or indirectly.
- the present invention relates to a compound of formula I
- R x is hydrogen, -C,, straight or branched chain alkyl, C 2 - C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or AT J .;
- R 2 is straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar 1# wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, C x -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, dialkyl, halogen, or Ar ⁇ , provided that both R 3 and R 4 are not hydrogen.
- alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl groups other than R 3 and R 4 may be optionally substituted with C 3 -C 8 cycloalkyl, C 3 or C 5 cycloalkyl, C 5 -C, cycloalkenyl, C L -C 4 alkyl, -Q, alkenyl, halo, hydroxy, carboxy, nitro, trifluoromethyl , -C ⁇ straight or branched chain alkyl or alkenyl, C 1 - C i alkoxy, -C, alkenyloxy, phenoxy, benzyloxy, or Ar l; and where Ar ⁇ is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 4-indolyl, 2-furyl, 3-furyl, tetrahydrofuranyl,
- R ⁇ and R 2 groups are either straight or branched aliphatic substituents or carbocyclic substituents illustrated by the compounds selected from the group of formula I :
- R is hydrogen, C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, 1-naphthyl, 2- naphthyl , or phenyl ;
- R 2 is -Cc, straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 3 -C 7 cycloalkenyl, 1-naphthyl, 2- naphthyl, or phenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, 1-naphthyl, 2-naphthyl, or phenyl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, dialkyl , halogen, or Ar x , provided that both R 3 and R 4 are not hydrogen.
- R x is either a straight or branched aliphatic group or a carbocyclic group
- R 2 is ethyl which is substituted with a carboxylic acid
- R is either a straight or branched aliphatic group or a carbocyclic group
- R 2 is ethyl which is substituted with a carboxylic acid
- R ⁇ is a straight or branched aliphatic group or a carbocyclic group
- R 2 is phenyl are selected from the group consisting of:
- R ⁇ is a straight or branched aliphatic group or a carbocyclic group and R 2 is ethyl which is substituted with carboxylic acid
- R ⁇ is a straight or branched aliphatic group or a carbocyclic group and R 2 is an
- C 2 -C 8 alkyl or alkenyl chain which is substituted with a carboxylic acid Exemplary species include:
- hydroxyphosphinyl derivatives wherein R x is benzyl and R 2 is a straight or branched aliphatic group or a carbocyclic group.
- Exemplary species include: 3- (benzylhydroxyphosphinyl) -3 -prop-2-enyl-2-methylpropanoic acid;
- R x is said alkyl, alkenyl, cycloalkyl, or aryl group which is substituted with a heterocyclic group and R 2 is ethyl which is substituted with a carboxylic acid are selected from the group consisting of:
- R is said alkyl, alkenyl, cycloalkyl, or aryl group which is substituted with a heterocyclic group and R 2 is phenyl are selected from the group consisting of :
- Especially preferred methods use compounds wherein Ri is benzyl and R 2 is said alkyl, alkenyl, cycloalkyl, or aryl group which is substituted with a heterocyclic group are selected from the group consisting of:
- R groups are heterocyclic substituents illustrated by the compounds selected from the group having formula I:
- R is C-,-C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar x , wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, straight or branched chain alkyl, C 2 -C 5 straight or branched chain alkenyl, dialkyl, halogen, or Ar x , provided that both R 3 and R 4 are not hydrogen.
- Especially preferred methods use compounds wherein R x is a heterocyclic group and R 2 is ethyl which is substituted with carboxylic acid are selected from the group consisting of: 2- [1- [ (2 -pyridyl) hydroxyphosphinyl] ethyl] pentanedioic acid; 2- [1- [ (3 -pyridyl) hydroxyphosphinyl] propyl] pentanedioic acid; 2- [1- [ (4 -pyridyl) hydroxyphosphinyl] butyl] pentanedioic acid; 2- [1- [ (tetrahydrofuranyl) hydroxyphosphinyl] but -3 -enyl] pentan
- R x is a heterocyclic group and R 2 is phenyl are selected from the group consisting of:
- R is hydrogen, -C;, straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar x ;
- R 2 is Ar lr wherein said aryl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, dialkyl , halogen, or Ar 17 provided that both R 3 and R 4 are not hydrogen.
- Particular species wherein R 2 is heterocyclic may be easily made and used by persons of ordinary skill in the art in accordance with the teachings provided herein and known in the art .
- R x is benzyl and R 2 is heterocyclic are selected from the group consisting of :
- the compounds of the present invention can be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathways depicted below (see Schemes I -IX) .
- Precursor compounds may be prepared by methods known in the art, such as those described in the method of Jackson et al . (J " . Med. Chem. 39(2), 619-622, Design. Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated a-Linked Acidic Dipeptidase) and, for example, in Froestl et al . ⁇ J. Med. Chem . , 1995, 38, 3313-3331, Phosphinic Acid Analogues of GABA) .
- R' (CH 2 ) 3 Ph H n-C 7 H 15 B. (CH,) 4 Ph I n- ⁇ C 9 H 17 C. (CH,) ⁇ Ph J n- ⁇ C q H, D. (CH 2 ) 4 (P-F-Ph) K n- • C 10 H 2 E . (CH 2 ) 4 - (3 -pyridyl) L CH, ( CH, ) (CH 3 C 4 Hg F. n-C.H, M CH. ( CH, ) CH ( CH,
- R' n-C 4 H Q 0. CH(CH,)C ⁇ H, ⁇
- Scheme IV and Scheme V Another route for preparing the compounds of the present invention is as set forth below in scheme IV and Scheme V.
- Scheme IV and Scheme V also show a phosphinic acid derivative as a starting material to prepare the compounds of the present invention and the R group is contemplated as including any reasonable chemical substitution and includes without limitation the R groups listed in Scheme II and within the specification.
- Scheme IX and Scheme X Another route for preparing the compounds of the present invention is as set forth below in Scheme IX and Scheme X.
- Scheme IX and Scheme X also show a phosphinic acid derivative as a starting material to prepare the compounds of the present invention and the R and R' groups are contemplated as including any reasonable chemical substitution and include without limitation the R groups listed in Scheme II and the R' groups listed in Scheme VIII and within the specification.
- compositions of the Present Invention also relates to a pharmaceutical composition comprising:
- the pharmaceutical composition further comprises a therapeutic agent selected from the group consisting of therapeutic hormones, chemotherapeutic agents, monoclonal antibodies, anti- angiogenesis agents, radiolabelled compounds, antineoplastic agents and mixtures thereof.
- therapeutic hormones include diethylstilbestrol (DES) , leuprolide, flutamide, cyproterone acetate, ketoconazole and amino glutethimide are preferred.
- antineoplastic agents include 5- fluorouracil , vinblastine sulfate, estramustine phosphate, suramin and strontium-89.
- chemotherapeutic agents include buserelin, chlorotranisene, chromic phosphate, cisplatin, cyclophosphamide , dexamethasone , doxorubicin, estradiol, estradiol valerate, estrogens conjugated and esterified, estrone, ethinyl estradiol, floxuridine, goserelm, hydroxyurea, melphalan, methotrexate, mitomycin and prednisone .
- the compound of formula I is present in an amount that is effective for inhibiting NAALADase activity in an animal or treating a prostate disease in an animal .
- a process for preparing a pharmaceutical composi-tion or medicament containing a compound of the present invention for treating a disease is also contemplated.
- the present invention further relates to a method of inhibiting NAALADase enzyme activity in an animal, comprising administering an effective amount of a compound of formula I to said animal .
- the present invention also relates to a method of treating a prostate disease in an animal, comprising administering an effective amount of a compound of formula I to said animal .
- said prostate disease is prostate cancer such as prostatic adenocarcinoma, benign prostatic hyperplasia, or conditions involving the prostate requiring administration of the compounds of the present invention, such prostatic intraepithelial neoplasia (PIN) .
- cancers of the present invention include without limitation: ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain -cancer, - breast cancer, cervix cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T- cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non- Hodgkin's lymphoma
- the compounds of the present invention are particularly useful in treating cancer of tissues where NAALADase enzymes reside.
- tissues include the prostate as well as the brain, kidney and testis.
- NAALADase inhibitor based drugs are used as an immediate initial therapy prior to surgery and radiation therapy, and as a continuous post -treatment therapy in patients at risk for recurrence or metastasis (based upon high PSA, high Gleason's score, locally extensive disease, and/or pathological evidence of tumor invasion in the surgical specimen) .
- the goal in these patients is to inhibit the growth of potentially metastatic cells from" the primary tumor during surgery or radiotherapy and inhibit the growth of tumor cells from undetectable residual primary tumor.
- NAALADase inhibitor based drugs are used as a continuous supplement to, or possible as a replacement for hormonal ablation. The goal in these patients is to slow tumor cell growth from both the untreated primary tumor and from the existing metastatic lesions.
- the invention may be particularly efficacious during post-surgical recovery, where the present compositions and methods may be particularly effective in lessening the chances of recurrence of a tumor engendered by shed cells that cannot be removed by surgical intervention.
- the present invention also includes a diagnostic kit for performing the methods of the present invention and may contain compounds and/or compositions containing the compounds of the present invention. Radiolabelled compounds and monoclonal antibodies may be used in a manner so as to provide diagnostic information. Examples of diagnostic information and uses include determining the type of disease, the progress of the particular disease, the location of cells targeted by a NAALADase inhibitor, radiolabelled compound or monoclonal antibody, and similar diagnostic uses known to persons skilled in the art .
- the compounds may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneal , intrathecal, intraventricular, intrasternal or intracranial injection and infusion techniques. Invasive techniques are preferred, particularly direct administration to damaged neuronal tissue.
- the compounds of the present invention should readily penetrate the blood-brain barrier when peripherally administered.
- Compounds which cannot penetrate the blood- brain barrier can be effectively administered by an intraventricular route .
- the compounds may also be administered in the form of sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparations may also be sterile injectable solutions or suspensions in non- toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1 , 3 -butanediol .
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile fixed oils are conventionally- -employed as solvents or suspending mediums.
- any bland fixed oil such as a synthetic mono- or di-glyceride may be employed.
- Fatty acids such as oleic acid and its glyceride derivatives, including olive oil and castor oil, especially in their polyoxyethylated forms, are useful in the preparation of injectables.
- These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.
- the compounds may be administered orally in the form of capsules, tablets, aqueous suspensions or solutions. Tablets may contain carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate.
- Capsules may contain diluents including lactose and dried corn starch.
- Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient .
- the oral dosage forms may further contain sweetening and/or flavoring and/or coloring agents .
- compositions can be prepared by mixing the drug with suitable non- irritating excipients which are solid at room temperature, but liquid at rectal temperature such that they will melt in the rectum to release the drug.
- suitable non- irritating excipients include cocoa butter, beeswax and polyethylene glycols.
- the compounds may be administered topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin or the lower intestinal tract.
- the compounds can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline or, preferably, as a solution in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
- the compounds may be formulated into ointments, such as petrolatum.
- suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol , benzyl alcohol and water.
- Topical application to the lower intestinal tract can be effected in rectal suppository formulations (see above) or in suitable enema formulations.
- the compounds of the present invention may be administered by a single dose, multiple discrete doses or continuous infusion. Since the compounds are small, easily diffusible and relatively stable, they are well suited to continuous infusion. Pump means, particularly subcutaneous pump means, are preferred for continuous infusion.
- compositions and methods of the invention also may utilize controlled release technology.
- NAALADase inhibitors may be incorporated into a polymer matrix for controlled release over a period of days.
- Such controlled release films are well known to the art.
- polymers commonly employed for this purpose include nondegradable ethylene-vinyl acetate copolymer and degradable lactic acid-glycolic acid copolymers .
- Certain hydrogels such as poly (hydroxyethylmethacrylate) or poly (vinylalcohol) also may be useful.
- Dosage Dose levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels being about 0.1 mg to about 1,000 mg .
- the specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, in vi tro dosage-effect results provide useful guidance on the proper doses for patient administration.
- the compounds of the present invention are administered in lyophilized form.
- 1 to 100 mg of a compound of the present invention may be lyophilized in individual vials, together with a carrier and a buffer, such as mannitol and sodium phosphate.
- the compound may be reconstituted in the vials with bacteriostatic water before administration.
- the compounds of the present invention may be administered in combination with one or more therapeutic agents, including chemotherapeutic agents.
- chemotherapeutic agents including chemotherapeutic agents.
- TABLE I provides known median dosages for selected chemotherapeutic agents. Specific dose levels for these agents will depend upon considerations such as those identified above for the compounds of the present invention.
- any administration regimen regulating the timing and sequence of drug delivery can be used and repeated as necessary to effect treatment .
- Such regimen may include pretreatment and/or co- administration with additional therapeutic agents.
- the compounds of the present invention may be administered (i) prior to surgery or radiation treatment to reduce the risk of metastasis; (ii) during surgery or in conjunction with radiation treatment; and/or (iii) after surgery or radiation therapy to reduce the risk of recurrence and to inhibit the growth of any residual tumorous cells .
- the compounds of the present invention may be administered as a continuous supplement to, or as a replacement for, hormonal ablation in order to slow tumor cell growth in both the untreated primary tumor and the existing metastatic lesions.
- the methods of the present invention are particularly useful where shed cells could not be removed by surgical intervention. After post-surgical recovery, the methods of the present invention would be effective in reducing the chances of recurrence of a tumor engendered by such shed cells .
- PSA Prostate Specific Antigen
- Hormonal Therapy Hormonal ablation is the most effective palliative treatment for the 10% of patients with metastatic prostate cancer. Hormonal ablation by medication and/or orchiectomy is used to block hormones that promote further growth and metastasis of prostate cancer. With time, both the primary and metastatic tumors of virtually all of these patients become hormone-independent and resistant to therapy. Approximately 50% of patients with metastatic cancer die within three years after initial diagnosis, and 75% of such patients die within five years after diagnosis. Continuous supplementation with the compounds of the present invention may be used to prevent or reverse this potentially metastasis- permissive state. (iii) Chemotherapy
- the compounds of the present invention may also be used in combination with monoclonal antibodies to treat prostate cancer. Such combined treatment is particularly effective for patients with pelvic lymph node involvement, of which only 34% survive after 5 years .
- An example of such monoclonal antibodies is cell membrane- specific anti -prostate antibody.
- the present invention may also be used with immunotherapies based on polyclonal or monoclonal antibody- derived reagents .
- Monoclonal antibody-derived reagents are preferred. These reagents are well known in the art, and include radiolabelled monoclonal antibodies such as monoclonal antibodies conjugated with strontium-89. (v) Cryotherapy The methods of the present invention may also be used in conjunction with cryotherapy for treatment of prostate cancer.
- LNCAP cells a prostate cancer cell line
- quisqualate acid in concentrations ranging from 10 nM to 1 ⁇ M
- 2- (phosphonomethyl) pentanedioic acid in concentrations ranging from 100 pM to 10 nM
- FIGS. 1 and 2 present this data graphically and particularly illustrate the decrease in proliferation and thymidine uptake of cells treated with NAALADase inhibitors.
- the agents are simultaneously evaluated on a non-NAALADase containing prostate cell line, DU145 (Carter et al . , Proc .
- NAALADase inhibiting activity of the agents are uniquely responsible for their cytostatic effects on NAALADase containing prostate carcinoma cell lines.
- LNCAP cells are obtained from Dr. William Nelson at the Johns Hopkins School of Medicine in Baltimore, MD.
- DU145 cells are obtained from American Type Culture Collection (Rockville, MD) .
- Cells are grown in RPMI-1640 media supplemented with 10% heat-inactivated fetal calf serum, 2 mM- glutamine, 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin (Paragon) in a humidified incubator at 37°C in a 5% C0 2 /95% 0 2 atmosphere.
- the cells are suspended at 1 x 10 3 cells/ml in RPMI-1640 media and seeded into 24 -well plates at 500 ⁇ l per well. After 24 hours, various concentrations of quisqualic acid (Sigma) or the potent NAALADase inhibitor 2-
- LNCaP human prostate cancer cells were injected subcutaneously into the right flank of male nude mice.
- 2- (phosphonomethyl) pentanedioic acid a NAALADase inhibitor
- An additional group was included using a silicon polymer containing 2- (phosphonomethyl) pentanedioic acid which released approximately 0.25 ⁇ g/day of drug locally into the tumor.
- the 2- (phosphonomethyl) entanedioic acid polymer was changed two times per week. Tumor volumes were monitored for 42 days after the beginning of treatment.
- LNCaP is a human prostate cancer cell line that was established in 1973 from a pleural effusion of a patient who had been treated with 5-FU, doxorubicin, methotrexate, and CTX in the 3 months before the cell line was initiated. This line is androgen receptor positive and has been used in screening anticancer drugs that are targeted as hormone antagonists. LNCaP was grown in RPMI with 1.5 g NaHC03/L, 10% fetal bovine serum (FBS) , and 2 mM L-glutamine and was kept at 37°C in a humidified 5% C0 2 /0 2 incubator. Antibiotics were not added to the medium.
- FBS fetal bovine serum
- NCr nude (nu/nu) male mice age 4-5 weeks, were purchased from Taconic (Germantown, NY) .
- the animals were housed four per cage in sterile filter-topped cages in a ventilated cage rack. Upon arrival, they were quarantined for four working days before use. Temperature was maintained at 72 ⁇ 5°F and relative humidity at 35-70%, and a 12 -hr light/dark cycle is used.
- the mice were fed sterile, autoclavable, certified Purina rodent chow ad libi tum. Drinking water was acidified and autoclaved, and the source water was recirculated, deionized, UV-treated, and 5- ⁇ m filtered.
- 2- (phosphonomethyl) pentanedioic acid was made up in water at a concentration of 2.5 mg/ml .
- Polymer containing 2- (phosphonomethyl) pentanedioic acid was made up by grinding 140 mg NaCl to a fine powder then mixing with 5mg 2- (phosphonomethyl) pentanedioic acid and 350 mg silicone gel. The mixture was spread to a thin film and allowed to dry for 24 hours. The material was cut into 1-1.5 mg pieces for subcutaneous implantation.
- mice When the tumor volumes reached a predetermined size (mean tumor volume 50-70 mm 3 ) , mice were added randomly into treatment groups of six to eight mice each. All treatments were administered daily for at least 4 weeks. 2- (phosphonomethyl ) pentanedioic acid was administered intratumorally daily in a volume of 0.05 -ml containing 0..025 ⁇ g 2- (phosphonomethyl) pentanedioic acid per injection.
- Polymer containing 2- (phosphonomethyl) pentanedioic acid (10 ⁇ g drug/mg polymer) was implanted subcutaneously . Mice were anaesthetized with metafane, and a small ( ⁇ 2mm) incision was made near the tumor site. Following implantation, the incision was closed with a wound clip. Polymer was replaced twice weekly.
- the tumor were measured twice weekly for at least 8 weeks after the first treatment.
- the mean tumor volume for each group was calculated for each time point. Comparisons between groups at specific times were made using an unpaired, two-tailed t-test, and the results were analyzed using analysis of variance (ANOVA) .
- R3327-G is a cell line derived from an androgen-sensitive papillary adenocarcinoma derived from a spontaneously forming tumor in the rat prostate.
- R3327-G cells were grown in RPMI, 10% fetal bovine serum (FBS) , 2 mM L-glutamine, and 10-8 M dexamethasone . Cultures were kept at 37°C in a humidified 5% C0 2 /0 2 incubator. Antibiotics were not added to the medium.
- Copenhagen male rats age 8-10 weeks, were purchased from Harlan Sprague Dawley (Indianapolis, IN) . The animals were housed two per cage. Upon arrival, they were quarantined for four working days before use . Temperature was maintained at 72 + 5°F and relative humidity at 35-70%, and a 12-hr light/dark cycle was used. The rats were fed certified Purina rodent chow and water ad libi tum .
- 2- (phosphonomethyl) pentanedioic acid was made up in physiological saline fresh each day prior to injection.
- a stock solution of 2 - [ [pheny lme t hy 1 ) hydroxyphosphiny1 ] methyl] pentanedioic acid was made up in water at a concentration 2.5 mg/ml ; ten- fold serial dilutions were made fresh weekly for injections .
- the rats were given daily subcutaneous injections of drug beginning the 14 days following tumor cell implantation and continued for 12 weeks.
- the drug was not administered until the tumor volumes reached a predetermined size (mean tumor volume 90- 290 mm 3 ) .
- the rats were divided into treatment groups of five rats each. All treatments of 2- [ [phenylmethyl) hydroxyphosphinyl] methyl] pentanedioic acid were subsequently administered intra-tumorally daily for 6 weeks.
- the tumors were measured twice weekly. The mean tumor volume for each group was calculated for each time point. Comparisons between groups at specific times were made using an unpaired, two-tailed t-test, and the results were analyzed using analyzed of variance (ANOVA) .
- ANOVA analyzed of variance
- Butylphosphinic Acid Piethyl chlorophosphite (25g, 0.16mol) in 60 mL of dry ether was cooled to 0°C under an atmosphere of nitrogen. Butylmagnesium chloride (80 mL, 0.16 mol, 2.0 M solution in ether) was added dropwise over a period of 2 hours while maintaining the internal temperature at 0°C. Once addition was complete the thick white slurry was heated to 30°C for 1 hour. The suspension was filtered under a nitrogen atmosphere and the filtrate evaporated under reduced pressure. The clear light yellow liquid was then brought up in 15 mL of water and stirred at room temperature. Concentrated hydrochloric acid (0.5 mL) was then added and an exothermic reaction was observed.
- Butyl f2 , 4-di (benzyloxycarbonyl) butyl] phosphinic acid Butylphosphinic acid (2.0g, 16mmol) in 80 mL of dry dichloromethane was cooled to 0°C under an atmosphere of nitrogen. Triethylamine (6.7 g, 66 mmol) was added followed by trimethylsilyl chloride (58 mL, 58 mmol, 1.0 M in dichloromethane) . The mixture was stirred at 0°C for 10 minutes and dibenzyl 2-methylenepentanedioate (2) (6.4 g, 20 mmol) in 20 mL of dichloromethane was added.
- Piethylchlorophosphite 25 g, 0.16 mol in 100 mL of dry diethyl ether was cooled to 0°C under an atmosphere of nitrogen.
- Benzylmagnesium chloride 80 mL, 0.16 mol, 2.0 M solution in Et 2 0
- a thick white slurry formed and stirring was continued at room temperature for 1 hour.
- the mixture was filtered under a nitrogen atmosphere and the filtrate evaporated under reduced pressure to give a clear and colorless liquid.
- the liquid was stirred as 15 mL of water was added followed by 0.5ml concentrated hydrochloric acid.
- Benzyl ⁇ 2 , 4-di (benzyloxyxcarbonyl ) butyl 1 hosphinic acid Benzylphosphinic acid (2.3 g, 15 mmol) in 150 mL of dry dichloromethane was cooled to 0°C under a nitrogen atmosphere. Triethylamine (6.5 g, 65mmol) was added followed by trimethylsilyl chloride (5.8 g, 54 mmol) while the reaction temperature was maintained at 0°C. After 30 minutes dibenzyl 2-methylenepentanediote (2) in 20 mL of dichloromethane was added over 5 minutes. The reaction mixture was left to warm to room temperature and stirred overnigh .
- Pry phosphinic acid 100 g, 1.52 mol was dissolved in 100 ml of chloroform and treated with triethylamine (155 g, 1.52mol) .
- the mixture was evaporated and transferred to a three liter flask, containing 750 mL of chloroform. The solution was stirred by means of a mechanical stirrer and the flask cooled to 0°C.
- the clear solution was treated with triethylamine (277 g, 2.72 mol) followed by trimethylsilyl chloride (281 g, 2.58 mol) .
- dibenzyl 2-methylenepentanedioate (2) in 150 mL of chloroform was added dropwise over 20 minutes. .
- the -low temperature bath was removed and the mixture warmed to room temperature.
- the thick slurry was filtered and the filtrate cooled to 0°C.
- the filtrate was then quenched with 5% hydrochloric acid and the organic layer removed.
- the aqueous layer was extracted with chloroform, the organics combined, dried (MgS0 4 ) and evaporated under reduced pressure to give 55 g of 2 , 4-di (benzyloxycarbonyl) butylphosphinic acid (6) as a light yellow liquid.
- a patient is diagnosed with adenocarcinoma of the prostate.
- the patient may then be administered a NAALADase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor.
- the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by subdural pump. It would be expected that no further occurrences of the adenocarcinoma would develop.
- EXAMPLE 16 A patient is diagnosed with adenocarcinoma of the prostate. The patient may then be administered a NAALADase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor. After this initial treat ent, the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by implantation of a biocompatible, polymeric matrix delivery system. It would be expected that no further occurrences of the adenocarcinoma would develop.
- a NAALADase inhibitor such as set forth in examples 1 through 3
- EXAMPLE 17 A patient is diagnosed with benign prostatic hyperplasia. The patient may then be administered a NAALADase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor. After this initial treatment, the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by injection, subdural pump, or polymeric matrix implant. It would be expected that the benign prostatic hyperplastic cells do not develop into carcinoma.
- a NAALADase inhibitor such as set forth in examples 1 through 3
- the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by injection, subdural pump, or polymeric matrix implant. It would be expected that the benign prostatic hyperplastic cells do not develop into carcinoma.
- EXAMPLE 18 A patient is diagnosed with adenocarcinoma of the prostate. The adenocarcinoma appears not to have metastasized. The adenocarcinoma would be removed by surgery. After pos -operative recovery, the patient would be locally administered NAALADase inhibitor by intermittent or continuous administration by injection, subdural pump or by polymeric matrix implant. It would expected that no further occurrences of the carcinoma would develop. EXAMPLE 19
- a patient is diagnosed with metastatic adenocarcinoma of the prostate .
- the adenocarcinoma appears to have metastasized, but surgery still is indicated as an effective treatment modality.
- Tumor tissue would be removed by surgery.
- the patient would be locally administered a NAALADase inhibitor such as described herein from the time, approximately, of the initial diagnosis and would continue after surgery. After post-operative recovery, the patient would be maintained at this level of NAALADase inhibitor by a regimen of periodic local administration.
- the patient would be monitored carefully for intolerable adverse side-effects of NAALADase inhibitor administration. It would be expected that no further tumors develop. If some of the original, small tumorous masses are detected after surgery, they would be expected to not grow in size.
- EXAMPLE 20 A patient is diagnosed with ACTH- roducing tumors. The patient may then be administered a NAALAPase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor. After this initial treatment, the patient may be optionally administered the same or different NAALAPase inhibitor by direct injection, subdural pump, or implantation of a biocompatible, polymeric matrix delivery system. It would be expected that tumor growth or tumor cell growth would be prevented or inhibited and that no further occurrences of the ACTH-producing tumor would develop.
- a NAALAPase inhibitor such as set forth in examples 1 through 3
- EXAMPLE 21 A treatment such as that described in Example 9 wherein the patient is diagnosed with acute lymphocytic leukemia.
- EXAMPLE 22 A treatment such as that described in Example 9 wherein the patient is diagnosed with acute non-lymphocytic leukemia.
- EXAMPLE 23 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cancer of the adrenal cortex.
- EXAMPLE 24 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic bladder cancer.
- EXAMPLE 25 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic brain cancer.
- EXAMPLE 26 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic brain cancer.
- EXAMPLE 27 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cervical cancer.
- EXAMPLE 28 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic chronic lymphocytic leukemia.
- EXAMPLE 29 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic chronic myelocytic leukemia.
- EXAMPLE 30 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic colorectal cancer.
- EXAMPLE 31 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cutaneous T-cell lymphoma.
- EXAMPLE 32 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic endometrial cancer.
- EXAMPLE 33 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic endometrial cancer.
- EXAMPLE 34 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Ewing's sarcoma.
- EXAMPLE 35 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic gallbladder cancer.
- EXAMPLE 36 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic hairy cell leukemia.
- EXAMPLE 37 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic head and neck cancer.
- EXAMPLE 38 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Hodgkin' s lymphoma.
- EXAMPLE 39 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Kaposi's sarcoma.
- EXAMPLE 40 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Kaposi's sarcoma.
- EXAMPLE 41 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic liver cancer.
- EXAMPLE 42 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic lung cancer (small cell and/or non-small cell) .
- EXAMPLE 43 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic malignant peritoneal effusion.
- EXAMPLE 44 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic malignant pleural effusion.
- EXAMPLE 45 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic melanoma.
- EXAMPLE 46 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic mesothelioma .
- EXAMPLE 47 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic multiple myeloma.
- EXAMPLE 48 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic multiple myeloma.
- EXAMPLE 49 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic non-Hodgkin' s lymphoma.
- EXAMPLE 50 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic osteosarcoma.
- EXAMPLE 51 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic ovarian cancer (and/or germ cell ovarian cancer) .
- EXAMPLE 52 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic pancreatic cancer.
- EXAMPLE 53 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic penis cancer.
- EXAMPLE 54 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic retinoblastom .
- EXAMPLE 55 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic skin cancer.
- EXAMPLE 56 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic skin cancer.
- Example 9 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic soft-tissue sarcoma.
- EXAMPLE 57 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic squamous cell carcinoma.
- EXAMPLE 58 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic squamous cell carcinoma.
- EXAMPLE 59 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic testicular cancer.
- EXAMPLE 60 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic thyroid cancer.
- EXAMPLE 61 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic trophoblastic neoplasm.
- EXAMPLE 62 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic uterine cancer.
- EXAMPLE 63 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic uterine cancer.
- EXAMPLE 64 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cancer of the vulva.
- EXAMPLE 65 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cancer of the vulva.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU39821/97A AU739443B2 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
EP97937265A EP0994707A4 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
CA002291258A CA2291258A1 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
JP50191298A JP2002514158A (en) | 1997-05-27 | 1997-08-15 | Inhibitors of NAALADase enzyme activity |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/858,985 | 1997-05-27 | ||
US08/863,624 | 1997-05-27 | ||
US08/863,624 US6046180A (en) | 1996-06-17 | 1997-05-27 | NAALADase inhibitors |
US08/858,985 US6025344A (en) | 1996-06-17 | 1997-05-27 | Certain dioic acid derivatives useful as NAALADase inhibitors |
US08/864,545 | 1997-05-28 | ||
US08/864,545 US6011021A (en) | 1996-06-17 | 1997-05-28 | Methods of cancer treatment using naaladase inhibitors |
US08/900,194 | 1997-07-25 | ||
US08/900,194 US6025345A (en) | 1996-06-17 | 1997-07-25 | Inhibitors of NAALADase enzyme activity |
ZA977087A ZA977087B (en) | 1996-06-17 | 1997-08-08 | Methods of cancer treatment using naaladase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998053812A1 true WO1998053812A1 (en) | 1998-12-03 |
Family
ID=27542266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/014347 WO1998053812A1 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0994707A4 (en) |
WO (1) | WO1998053812A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038785A2 (en) * | 1998-12-31 | 2000-07-06 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
WO2001034596A2 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
EP1212055A1 (en) * | 1999-08-16 | 2002-06-12 | Revaax Pharmaceuticals LLC | Neurotherapeutic composition and method |
US6586623B2 (en) * | 2001-01-17 | 2003-07-01 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
WO2006054182A2 (en) * | 2004-09-16 | 2006-05-26 | Idenix Pharmaceuticals, Inc. | Phosphoindoles as hiv inhibitors |
DE102006010362A1 (en) * | 2006-03-07 | 2007-09-13 | Clariant International Limited | Mixtures of mono-carboxyl-functionalized dialkylphosphinic acids, a process for their preparation and their use |
US7399461B2 (en) | 1993-11-05 | 2008-07-15 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US7960428B2 (en) | 2006-09-29 | 2011-06-14 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as HIV inhibitors |
WO2011073286A1 (en) | 2009-12-18 | 2011-06-23 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
CN101084231B (en) * | 2004-09-17 | 2011-08-24 | 埃迪尼克斯医药公司 | Phosphoindoles as HIV inhibitors |
US8008325B2 (en) | 2002-03-21 | 2011-08-30 | Bayer Schering Pharma Ag | Plasma carboxypeptidase B inhibitors |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
US8114965B2 (en) | 2001-10-23 | 2012-02-14 | Psma Development Company, Llc | Compositions of PSMA antibodies |
USRE43586E1 (en) | 1992-11-05 | 2012-08-14 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
EP2567696A1 (en) | 2006-11-22 | 2013-03-13 | Seaside Therapeutics, Inc. | Compositions for treating autism spectrum disorder |
US8470330B2 (en) | 2001-10-23 | 2013-06-25 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4602092A (en) * | 1983-09-19 | 1986-07-22 | E. R. Squibb & Sons, Inc. | Method for making phosphinic acid intermediates |
US4988681A (en) * | 1988-06-23 | 1991-01-29 | Banyu Pharmaceutical Co., Ltd. | Phosphinic acid derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5500420A (en) * | 1993-12-20 | 1996-03-19 | Cornell Research Foundation, Inc. | Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia |
ID18382A (en) * | 1996-09-27 | 1998-04-02 | Guilford Pharm Inc | PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS |
-
1997
- 1997-08-15 EP EP97937265A patent/EP0994707A4/en not_active Withdrawn
- 1997-08-15 WO PCT/US1997/014347 patent/WO1998053812A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4602092A (en) * | 1983-09-19 | 1986-07-22 | E. R. Squibb & Sons, Inc. | Method for making phosphinic acid intermediates |
US4988681A (en) * | 1988-06-23 | 1991-01-29 | Banyu Pharmaceutical Co., Ltd. | Phosphinic acid derivatives |
Non-Patent Citations (2)
Title |
---|
JACKSON P. F., ET AL.: "DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY OF A POTENT INHIBITOR OF THE NEUROPEPTIDASE N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE.", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39., no. 02., 19 January 1996 (1996-01-19), US, pages 619 - 622., XP002072189, ISSN: 0022-2623, DOI: 10.1021/jm950801q * |
See also references of EP0994707A4 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43586E1 (en) | 1992-11-05 | 2012-08-14 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US7399461B2 (en) | 1993-11-05 | 2008-07-15 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
WO2000038785A3 (en) * | 1998-12-31 | 2000-09-21 | Guilford Pharm Inc | Methods for treating certain diseases using naaladase inhibitors |
WO2000038785A2 (en) * | 1998-12-31 | 2000-07-06 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
US6806261B2 (en) | 1998-12-31 | 2004-10-19 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
EP1371367A1 (en) * | 1998-12-31 | 2003-12-17 | Guilford Pharmaceuticals Inc. | Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases |
EP1212055A1 (en) * | 1999-08-16 | 2002-06-12 | Revaax Pharmaceuticals LLC | Neurotherapeutic composition and method |
US7842683B2 (en) | 1999-08-16 | 2010-11-30 | Revaax Pharmaceuticals, Llc | Neurotherapeutic compositions and method |
EP1212055A4 (en) * | 1999-08-16 | 2005-09-07 | Revaax Pharmaceuticals Llc | Neurotherapeutic composition and method |
WO2001034596A3 (en) * | 1999-11-12 | 2002-03-07 | Guilford Pharm Inc | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
WO2001034596A2 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
WO2001092273A3 (en) * | 2000-05-30 | 2002-07-25 | Guilford Pharm Inc | Benzenedicarboxylic acid derivatives |
WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
US6812364B2 (en) | 2001-01-17 | 2004-11-02 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US6992215B2 (en) | 2001-01-17 | 2006-01-31 | Guildford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US6586623B2 (en) * | 2001-01-17 | 2003-07-01 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US9695248B2 (en) | 2001-10-23 | 2017-07-04 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
US8470330B2 (en) | 2001-10-23 | 2013-06-25 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
US8114965B2 (en) | 2001-10-23 | 2012-02-14 | Psma Development Company, Llc | Compositions of PSMA antibodies |
US8008325B2 (en) | 2002-03-21 | 2011-08-30 | Bayer Schering Pharma Ag | Plasma carboxypeptidase B inhibitors |
WO2006054182A2 (en) * | 2004-09-16 | 2006-05-26 | Idenix Pharmaceuticals, Inc. | Phosphoindoles as hiv inhibitors |
US7534809B2 (en) | 2004-09-17 | 2009-05-19 | Idenix Pharmaceuticals, Inc. | Phospho-indoles as HIV inhibitors |
US8044091B2 (en) | 2004-09-17 | 2011-10-25 | Idenix Pharmaceuticals, Inc. | Phospho-indoles as HIV inhibitors |
WO2006054182A3 (en) * | 2004-09-17 | 2007-03-01 | Idenix Pharmaceuticals Inc | Phosphoindoles as hiv inhibitors |
CN101084231B (en) * | 2004-09-17 | 2011-08-24 | 埃迪尼克斯医药公司 | Phosphoindoles as HIV inhibitors |
AU2005305609B2 (en) * | 2004-09-17 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Phosphoindoles as HIV inhibitors |
US8097753B2 (en) | 2006-03-07 | 2012-01-17 | Clariant Finance (Bvi) Limited | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation |
DE102006010362A1 (en) * | 2006-03-07 | 2007-09-13 | Clariant International Limited | Mixtures of mono-carboxyl-functionalized dialkylphosphinic acids, a process for their preparation and their use |
US7960428B2 (en) | 2006-09-29 | 2011-06-14 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as HIV inhibitors |
US8486991B2 (en) | 2006-09-29 | 2013-07-16 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as HIV inhibitors |
EP2567696A1 (en) | 2006-11-22 | 2013-03-13 | Seaside Therapeutics, Inc. | Compositions for treating autism spectrum disorder |
EP2578216A1 (en) | 2006-11-22 | 2013-04-10 | Seaside Therapeutics, Inc. | Methods of treating fragile x syndrome |
WO2011073286A1 (en) | 2009-12-18 | 2011-06-23 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
EP2338892A1 (en) | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
Also Published As
Publication number | Publication date |
---|---|
EP0994707A1 (en) | 2000-04-26 |
EP0994707A4 (en) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6046180A (en) | NAALADase inhibitors | |
US6011021A (en) | Methods of cancer treatment using naaladase inhibitors | |
US6025344A (en) | Certain dioic acid derivatives useful as NAALADase inhibitors | |
US5804602A (en) | Methods of cancer treatment using naaladase inhibitors | |
US5968915A (en) | Naaladase inhibitors | |
US6025345A (en) | Inhibitors of NAALADase enzyme activity | |
US5863536A (en) | Phosphoramidate derivatives | |
US5795877A (en) | Inhibitors of NAALADase enzyme activity | |
US6054444A (en) | Phosphonic acid derivatives | |
EP0994707A1 (en) | Inhibitors of naaladase enzyme activity | |
US6372726B1 (en) | Methods of cancer treatment using NAALADase inhibitors | |
JP2001527084A (en) | Prodrugs of NAALDase inhibitors | |
WO1999033847A1 (en) | Phosphinic alkanoic acid derivatives | |
AU739443B2 (en) | Inhibitors of naaladase enzyme activity | |
CZ390198A3 (en) | Use of NAALADase inhibitor when preparing medicament for treating cancer, suppression of tumor cell growth or disorder relating to NAALADase enzyme activity in animal | |
MXPA00006283A (en) | Prodrugs of naaladase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997937265 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2291258 Country of ref document: CA Ref country code: CA Ref document number: 2291258 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997937265 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997937265 Country of ref document: EP |